

CURRICULUM VITAE

November 6, 2008

Name: Arshag D. Mooradian

Citizenship: U.S.A.

Marital status: Married

Children: Arshag Jr., born 06/01/1986
Ariana, born 08/26/1989

Address: Department of Medicine
University of Florida
653-1 West 8th Street
4th Floor - LRC
Jacksonville, FL 32209

Phone: (904)-244-8846

Fax: (904)-244-8844

E-mail: arshag.mooradian@jax.ufl.edu

Undergraduate Education:

American University of Beirut	1973-1976	B.Sc. With High Distinction
American University of Beirut	1976-1980	M.D. with Distinction and Penrose Award

Post-Graduate Training:

American University Hospital	7/1/79 - 6/30/80	Internship (straight) in Internal Medicine
American University Hospital	7/1/80 - 6/30/82	Residency(Internal Medicine)
University of Minnesota	7/1/82 - 6/30/85	Fellowship - Endocrinology

CERTIFICATIONS AND LICENSURES:

I. General:

Bachelor of Sciences (B.Sc. in Biology), 1976

National Board Examination (Part I), 1977

National Board Examination (Part II), 1979

E.C.F.M.G. Certification, 1979

Doctor of Medicine (M.D.), 1980

F.L.E.X. Certification, 1980

A.C.L.S. Certification, 1984

II. Specialty Boards:

Internal Medicine (Certified, 09/16/1987)

Endocrinology, Diabetes and Metabolism (Certified, 11/07/89)

Geriatric Medicine (Certified, 01/01/1990)

III. Professional Licenses:

New York State (1981)	License No. 145493
Minnesota (1982)	License No. 27670
California (1985)	License No. C41800
Arizona (1988)	License No. 18049
Missouri (1991)	License No. MDR1P91
Illinois (1992)	License No. 003-036-084534-01
Florida (2006)	License No. ME 95499

Academic and Professional Appointments:

University of Florida	5/1/2006 - Present	Chairman; Department of Medicine
University of Florida	5/1/2006 - Present	Professor of Medicine Tenured: 5/1/2006
Shands Hospital-Jacksonville	5/1/2006- Present	Chief; Medical Service
Saint Louis University	7/1/1991 - 5/14/2006	Director, Division of Endocrinology, Diabetes and Metabolism
Saint Louis University	7/1/1991 - 5/14/2006	Professor of Internal Medicine Tenured: 7/1/1992
Sun Yat-Sen University (People's Republic of China)	4/1/2001 - 4/1/2003	Professor of Internal Medicine/Endocrinology (Honorary)
St. Louis VA Medical Center	7/1/1991 - 5/1/2006	Staff Physician (WOC since 1997)
University of Arizona	7/1/1988 - 6/30/1991	Associate Professor of Internal Medicine Tenured: 7/1/1989
Tucson VA Medical Center	7/1/1988 - 6/30/1991	Staff Physician
University of Arizona	7/1/1988 - 6/30/1991	Director of Gerontological Research
University of California Los Angeles	7/1/1985 - 6/30/1988	Assistant Professor of Internal Medicine
Sepulveda VA Medical Center	7/1/1985 - 6/30/1988	Staff Physician

Honors and Awards:

1. Alpha Omega Alpha Honor Medical Society, 1979.
2. Phi Kappa Phi Honor Society, 1984.
3. Penrose Award, 1980.
4. N.I.H. Individual Fellowship Award 1984.
5. Veterans' Administration Merit Award: 1985.
6. Veterans' Administration Merit Award: 1987.
7. Veterans' Administration Merit Award: 1990.
8. Veterans' Administration Merit Award: 1993.
9. Who's Who in Science and Engineering, 1992-
10. Who's Who in the Midwest, 1993-
11. Who's Who in Medicine and Healthcare, 1995-
12. International Who's Who in Medicine, 1995-
13. Who's Who in America (51st edition) 1997-
14. Who's Who in American Education 2003-
15. Guide to America's Top Physicians 2003-

Professional Societies:

1. American Association for the Advancement of Science
2. The Endocrine Society
3. Gerontological Society of America
4. American Diabetes Association
5. Saint Louis Society of Internal Medicine
6. Association of Professors of Medicine (APM) 2006-

Editorial Boards:

1. Drugs 2007-Present
2. Drugs and Aging 1990-Present
3. Diabetes Spectrum 1992-1996
4. Journal of the American Geriatrics Society 1989-1992

Ad Hoc Reviewer For Grant Applications:

1. Veterans Affairs Research Service
2. National Institute of Health
3. Medical Research Council (Canada)
4. The Wellcome Trust
5. Texas Institute for Research and Education on Aging (TIREA)
6. Austrian Science Fund
7. Diabetes UK (the operating name of The British Diabetic Association)

Ad Hoc Reviewer For The Following Journals:

1. Acta Neurochirurgica
2. Acta Neuropathologica
3. The American Journal of Clinical Nutrition
4. The American Journal of Medicine
5. The American Journal of Physiology
6. The American Journal of Kidney Disease
7. The Archives of Internal Medicine
8. Biochimica et Biophysica Acta (BBA)
9. Brain Research
10. British Journal of Nutrition
11. British Journal of Pharmacology
12. Clinical Pharmacology and Therapeutics
13. Diabetes
14. Diabetes Care
15. Diabetic Medicine
16. Diabetes and Metabolism Research and Reviews
17. Diabetes Spectrum
18. Drugs
19. Drugs and Aging
20. Endocrinology
21. Endocrine
22. Life Sciences
23. Metabolism: Clinical and Experimental
24. Obesity
25. Journal of the American Geriatrics Society
26. Journal of Applied Physiology
27. Journal of Gerontology
28. Journal of Clinical Investigation
29. Journal of Clinical Endocrinology and Metabolism
30. Journal of Endocrinology
31. Journal of Laboratory and Clinical Medicine
32. Journal of Molecular Endocrinology
33. Journal of Molecular and Cellular Biochemistry
34. Journal of Neurochemistry
35. Journal of Nutrition, Health and Aging
36. Journal of Nutritional Biochemistry
37. Journal of Pharmacology and Experimental Therapeutics
38. Journal of Physiology
39. Molecular Endocrinology
40. Neurobiology of Aging
41. Neuroscience Letters
42. Nutrition
43. Pharmacological Research
44. Proceedings of the Society of Experimental Biology and Medicine.

National /Regional Committees:

1. Association of Professors of Medicine (APM), Communications Committee July 2008- June 2010.
2. Academic Medical Center (AMC) Advisory Board meeting; Pfizer Inc. 2008.
3. Committee for selection of Diabetes Visiting Professorship sponsored by Pfizer Inc. 2007 and 2008.
4. Reviewer for Effective Health Care Programs; the Agency for Healthcare Research and Quality, Rockville, MD. 2008.
5. American Diabetes Association Task Force for writing Nutrition Principles for the Management of Diabetes and Related Complications, 2005-2006.
6. Scientific Advisory Board of the American Society of Klinefelter's Syndrome, 2000-2005.
7. Society of Internal Medicine (St. Louis) President: Dec.2002-Dec. 2003
8. Society of Internal Medicine (St. Louis) President-elect: Dec.2001-Dec.2002.
9. Chairman of Council on Nutrition and Metabolism, the American Diabetes Association, 7/1/2000-7/1-2002.
10. American Diabetes Association Task Force for writing Nutrition Principles for the Management of Diabetes and Related Complications, 2000-2001.
11. American Diabetes Association Task Force on Diabetes in Older Adults, 1998.
12. V.A./JDF Diabetes Centers of Excellence Review Committee, 1998.
13. Chair, the American Diabetes Association Steering Committee for Continuing Education Programs on Diabetes in the Elderly, 1995-1997.
14. NIH/NIA Claude Pepper Centers Review Committee, 1995.
15. Chair of the American Diabetes Association Task Force on Micronutrients in Diabetes, 1990-1994.

Local Committees at the University of Florida:

1. Board of Directors, the University of Florida Jacksonville Healthcare, Inc. May 2006-Present.
2. Executive Committee, the University of Florida, College of Medicine Jacksonville, May 2006-Present.
3. Medical Executive Committee, Shands Hospitals, Jacksonville, FL. May 2006-Present.
4. Clinical Operations Committee, University of Florida Jacksonville Healthcare, Inc. May 2006-Present.
5. Executive Committee of the Department of Medicine, University of Florida College of Medicine, Jacksonville, May 2006-Present.
6. Search Committee for the Assistant Dean for Research, 2006.
7. Dean's advisory committee for development and promotion of research, October 2006-Present.
8. Scholarly activity taskforce for GME.
9. Academic achievement enhancement committee. 2006-
10. Chairman of the Search Committee for the Chairman of the Department of Surgery.
11. Chairman of the nominating committee for the University of Florida Jacksonville Healthcare, Inc (UFJHI) Board membership at large, August 2007.
12. Finance Committee of University of Florida Jacksonville Healthcare, Inc., August 2007-Present.
13. University of Florida Industry Conflict Task Force, November 2007-Present.
14. Planning and Development Committee, December 2007-Present.
15. International Healthcare Advisory Committee, May 2008-Present.
16. Chairman of the University of Florida COM-JAX Industry Conflict Task Force, May 2008-Present.
17. UF CTSA (Clinical and Translational Science Award) Scientific Advisory Board member, 2007-Present.
18. UF GRECC (Geriatric Research Education and Clinical Center) Advisory Board member, 2008-Present.

Local Committees at St. Louis University:

1. Executive Committee, Department of Internal Medicine, Saint Louis University, 1995-2006.
2. Board of Trustees Saint Louis University, Clinical Affairs Committee: December 2002- 2005.
3. Committee for Conflict of Commitment. 2004.
4. Residency Review Committee of the Division of Plastic Surgery, 2004.
5. Chairman of the Executive Committee of the University Medical Group (UMG), Saint Louis University, 4/2000-4/2002. (*Responsible for overseeing the implementation of policies and procedures as well as financial operations of the UMG*).
6. Governing Board of the University Medical Group (UMG), Saint Louis University, 4/2000- 4/2002.
7. Committee for negotiating Master Lease Agreement with Tenet Inc., 6/2002.
8. Physician's Incentive Compensation Committee, Saint Louis University, 1997-2000.
9. Residency Review Committee of the Department of Surgery, 2000.
10. Residency Review Committee of the Department of Psychiatry, 1998.
11. Residency Review Committee for the Department of Orthopedic Surgery, 1996.
12. Diabetes Advisory Committee of Saint Louis University, 1991-1997.
13. Ancillary Testing Committee, St. Louis V.A. Medical Center, 1994-1996.
14. Search Committee OB-Gyn Chairman, 1995-1997.

Organizer of Regional or National Educational Symposia:

1. Annual Symposium on Endocrinology and Diabetes, Saint Louis University, 1992, 1993, 1994, 1995, 1996, 1997, 1998, 1999, 2000, 2001, 2003.
2. St. Louis Endocrine Club: Quarterly Meetings, 1991-Present.
3. Directors of Endocrinology Meeting; Caribbean, 1996.
4. National Meeting: Diabetes in Older Adults, Cancun, Mexico, 1998.

Consultant for the following pharmaceutical companies:

1. Alza, Inc.
2. Eli Lilly, Co.
3. Merck, Sharp and Dohme
4. Novartis
5. Andrx Laboratories
6. Pfizer, Inc.
7. Cygnus Therapeutic Systems
8. Bayer Pharmaceutical Company
9. Parke-Davis
10. Alpha Therapeutics
11. Astra Merck
12. Nissan Pharmaceuticals
13. Williamson Major Group
14. Novo Nordisk
15. Toler Rx Inc.

Research Grants (Investigator initiated):

1. N.I.H. Individual Fellowship Award 1984; "Trans-cellular transport of thyroid hormone"
2. Veterans' Administration RAG Award: 1985-1987; Effect of age on the blood-brain barrier"; (Role: PI).
3. Burroughs Wellcome 1988-1991; "Preclinical trials of a novel class of gluconeogenesis inhibitors"; (Role: PI).

Research Grants (Investigator initiated) (cont'd):

4. Veterans' Administration Merit Award: 1985-1987; "Effect of age on the blood-brain barrier"; (Role: PI).
5. Veterans' Administration Merit Award: 1987-1990; "Effect of age and diabetes on the blood-brain barrier"; (Role: PI).
6. Veterans' Administration Merit Award: 1990-1993; "Effect of age and diabetes on the blood-brain barrier"; (Role: PI).
7. Veterans' Administration Merit Award: 1993-1997; (Role: PI) "Effect of age and diabetes on the blood-brain barrier"; (Role: PI).
8. Pfizer Investigator Initiated Grant 1995-1997; "The effect of Glipizide GITS on islet cell hormonal responses"; (Role: PI).
9. Bayer Investigator Initiated Grant 1997-1998; "Role of acarbose in the elderly diabetic subjects"; (Role: PI).
10. Thyroid Research Advisory Council Award 1998-2000; "Characterization of thyroid hormone responsive proteins in the brain"; (Role: PI).
11. Takeda Investigator Initiated Grant 1999-2001; "Mechanisms of apo AI expression in HepG2 cells; (Role: PI).
12. NHLBI. National Institute of Health, Grant # U01 HL61744-01; 3/1/2001-3/1/2008 "Bypass Angioplasty Revascularization Investigation in type 2 diabetes"; (Role: Site PI).
13. AstraZeneca Investigator Initiated Grant 2003-2004; "Diabetes-related alterations in endothelial barrier function: The role of Rho inactivation with rosuvastatin"; (Role: PI).
14. Merck Investigator Initiated Grant 2003-2004; "Amelioration of diabetes-related alterations in endothelial barrier function with simvastatin"; (Role: PI).
15. NIH- National Institute on Aging Small Business Innovation Research Grant 1 R43 AG028218-01 (SBIR) 2007-2009 "Formulated Phytosterols – A New Treatment for Benign Prostatic Hyperplasia," Protocol No. ZNX 1.003-C (Role: CO-PI)

Clinical Trials Funded by Pharmaceutical Industry:

1. Clinical trials of Simvastatin® (Merck, Sharp and Dohme); 1989-1991.
2. The role of growth hormone in the management of frail elderly (Genentech, Inc.); 1990-1992.
3. The role of growth factors in healing diabetic foot ulcers (Merck, Sharp and Dohme); 1992-1994.
4. The efficacy of enalapril/diltiazem combination in the treatment of essential hypertension (Merck, Sharp and Dohme); 1992-1994.
5. The efficacy of enalapril/Felodipine combination in the treatment of essential hypertension (Merck, Sharp and Dohme); 1992-1994.
6. The role of insulin analogues in the management of non-insulin dependent diabetic patients (Eli Lilly Co.); 1993-1994.
7. The safety and efficacy of Miglitol in non-insulin dependent diabetic patients (Miles, Inc.); 1994-1996.
8. The safety and efficacy of Glipizide GITS in Type II diabetes mellitus (Pratt/Pfizer); 1995-1996.
9. The pharmacokinetic comparison of serum testosterone levels following Testoderm I application compared to intramuscular Testosterone cypionate (Alza, Inc.); 1995-1996.
10. The pharmacokinetics of serum testosterone following Testoderm II applications (Alza, Inc.); 1995-1996.
11. A comparative study of Testoderm II and Androderm (Alza, Inc.); 1995-1996.
12. The safety and efficacy of pimagedine in the treatment of diabetic nephropathy of insulin dependent diabetic subjects (Hoechst Marion Merrell Dow); 1995-1999.
13. The safety and efficacy of pimagedine in the treatment of diabetic nephropathy of non-insulin dependent diabetic subjects (Hoechst Marion Merrell Dow); 1995-1999.
14. The role of Sibutramine in obese hypertensive patients on ACE inhibitors (Knoll Pharmaceutical); 1996-1997.
15. The role of Sibutramine in obese hypertensive patients treated with calcium channel blockers (Knoll Pharmaceutical); 1996-1997.

Projects Funded by Pharmaceutical Industry (cont'd):

16. The role of Sibutramine in the management of obese patients with Type II diabetes (Knoll Pharmaceutical); 1996-1997.
17. The comparative efficacy and safety of Bay W6228 400 µg compared to 200 µg once daily in primary hypercholesterolemia. (Bayer Corporation); 1996-1998.
18. The role of Amylin in management of Type I diabetes. (Amylin Pharmaceuticals); 1996-1998.
19. Management of diabetes in the elderly: role of voglibose (Takeda, Inc.); 1997-1999.
20. The efficacy of metformin-glyburide combination therapy in Type II diabetes (Bristol Myers Squibb); 1997-1998.
21. The efficacy and safety of nerve growth factor (NGF) in treatment of diabetic peripheral neuropathy. (Genentech, Inc.); 1997-1998.
22. The efficacy and safety of sildenafil in the treatment of erectile failure in diabetes. (Pfizer, Inc.); 1997-1998.
23. Safety and efficacy of fixed combination metformin/glyburide products as first line therapy in patients with type 2 diabetes. (Bristol Myers Squibb); 1998 – present.
24. The safety and efficacy of a long acting insulin analogue in the management of type 2 diabetes. (Hoechst Marion Roussel); 1998-present.
25. Comparison of an incremental weight-based dose regimen with an individualized dosage adjusted according to the IGF-1 response in adults with growth hormone deficiency (Eli Lilly Co.); 1998-2002.
26. Antiproteinuric effects of Omapatrilat and amlodipine in Type 2 diabetics with hypertension and microalbuminuria or overt nephropathy. Bristol Myers Squibb; 1998-1999.
27. Safety and efficacy of sibutramine 20 mg given in titrated doses to patient with obesity (Knoll Pharmaceutical) 1998-2000. (Bristol Myers Squibb) 1998-2000.
28. Pharmacokinetic studies of V2001: a novel hypoglycemic agent. (Purdue Pharmaceuticals); 1998-1999.
29. The efficacy of Avasimibe in patients with peripheral arterial disease. (Parke-Davis); 1999-2000.

Projects Funded by Pharmaceutical Industry (cont'd):

30. The role of Zenestatin in comparison to simvastatin and pravastatin in the treatment of hypercholesterolemia. (Zeneca Pharmaceuticals); 1999-2000.
31. Effects of chronic somatropin treatment on bone mineral density in patients diagnosed with adult onset growth hormone deficiency. (Eli Lilly); 1999-2001.
32. The efficacy of omapatrilat in hypertensive subjects poorly controlled on calcium channel blocker monotherapy. (Bristol Myers Squibb); 1999-2000.
33. The efficacy of omapatrilat in hypertensive subjects poorly controlled on ACE inhibitor monotherapy. (Bristol Myers Squibb); 1999-2000.
34. The efficacy of Orlistat plus diet as compared to Orlistat plus phentermine plus diet in severely obese patients. (Roche); 2000-2001.
35. The efficacy of cerivastatin in the treatment of osteoporosis in postmenopausal women (CHARMstudy). (SmithKline Beecham); 2000 - 2002.
36. The efficacy of omapatrilat in poorly controlled hypertensive subjects (OCTAVE) trial. (Bristol Myers Squibb); 2000-2001.
37. Safety and efficacy of fixed combination therapy of metformin/glipizide in Type 2 diabetic subjects. (Bristol Myers Squibb), 2000-2001.
38. Efficacy, safety and tolerability of metformin ER and metformin immediate release in Type 2 diabetes mellitus. (Depo Med Inc.), 2001-2002.
39. Randomized, double blind multicenter study comparing glycemic control characteristics of carvedilol and metoprolol in hypertensive patients with Type 2 diabetes mellitus. (Glaxo Smith Kline Beechem), 2001-2002.
40. Multicenter trial of raloxiphen and alendronate comparison in post menopausal women with osteoporosis. (Eli Lilly Co.) 2001-2005.
41. Phase II randomized, double blind , placebo controlled dose ranging study to determine the efficacy, tolerability and pharmacokinetics of RO 205-2349 in patients with type 2 diabetes. (Roche Pharmaceuticals) 2002-2003.

Projects Funded by Pharmaceutical Industry (cont'd):

42. Multicenter, randomized, double-blind study to evaluate the tolerability and efficacy of the co-administration of simvastatin and fenofibrate in patients with combined hyperlipidemia. Merck & Co. 2002.
43. Multicenter, randomized, double-blind study to evaluate the tolerability and efficacy of metformin/glipizide combination pill in subjects with type 2 diabetes. PPD Inc. 2002-2003.
44. A multicenter, double blind study to evaluate the effect of pre-treatment with a daily dose of viagra (sildenafil citrate) on the PRN efficacy of viagra in men with erectile dysfunction and type 2 diabetes, Pfizer Co. 2003-2004.
45. Clopidogrel for high atherothrombotic risk and ischemic stabilization, management and avoidance (CHARISMA). Sanofi Pharmaceuticals; 2003-2007.
46. A phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 in combination with glyburide therapy in subjects with type 2 diabetes who have inadequate glycemc control on sulfonylurea therapy alone. Bristol-Myers Squibb, 2003- 2004.
47. A phase 3, randomized, double-blind, placebo controlled, multicenter trial to evaluate the safety and efficacy of BMS-298585 in combination with metformin therapy in subjects with type 2 diabetes who have inadequate glycemc control on metformin therapy alone. Bristol-Myers Squibb, 2003-2004.
48. An-open label study to evaluate the efficacy and safety of tadalafil administered “on demand” to men of various populations with erectile dysfunction. Lilly/ICOS. 2003-2004.
49. A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment and 28 week extension with LAF237 (50mg qd or bid) to placebo as add-on therapy to glimepiride in patients with type 2 diabetes inadequately controlled with sulfonylurea monotherapy. Novartis. 2004-2005.
50. A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment and 28 week extension with LAF237 (50mg qd or bid) to placebo as add-on therapy to pioglitazone 45 mg qd in patients with type 2 diabetes inadequately controlled with thiazolidinedione monotherapy. Novartis, 2004-2005.

Projects Funded by Pharmaceutical Industry (cont'd):

51. A multicenter, double-blind, randomized, parallel-group study to compare the effect of 24 weeks treatment and 28 week extension with LAF237 (50mg qd or bid) to placebo as add-on therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Novartis, 2004-2005.
52. A double blind placebo controlled study of the effect of formulated soy sterols on circulating levels of testosterone and dihydrotestosterone. Life Technologies, 2004-2005.
53. The safety and efficacy of a combination of niacin ER and simvastatin in patients with dyslipidemia: a dose-ranging study. Kos Pharmaceuticals 2005-2006.
54. Apidra (insulin glulisine) administered premeal vs postmeal in adult subjects with type 2 diabetes mellitus receiving Lantus (insulin glargine) as basal insulin: a multicenter, randomized, parallel, open label clinical study. Aventis, 2005-2006.
55. A 24-week randomized, double-blind, multicenter, placebo-controlled study to evaluate the efficacy, safety and tolerability of tesaglitazar therapy when added to the therapy of patients with type 2 diabetes poorly controlled on insulin.(GALANT 9) , Astra Zeneca 2005-2006.
56. Double blind, placebo controlled, multicenter, pharmacokinetic, pharmacodynamic and tolerability study of ETC-588 in patients with stable atherosclerosis. Pfizer 2005-2006.
57. A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of fenofibric acid and rosuvastatin calcium combination therapy to fenofibric acid and rosuvastatin calcium monotherapy in subjects with mixed dyslipidemia. Abbott 2006-2007.
58. A multicenter, randomized, double-blind, prospective study comparing the safety and efficacy of fenofibric acid and simvastatin combination therapy to fenofibric acid and simvastatin monotherapy in subjects with mixed dyslipidemia. Abbott 2006-2007.

Visiting Professorships:

1. University of California in Los Angeles, Department of Internal Medicine. 1990.
2. Washington University, Department of Neurobiology, 1992
3. University of Wisconsin, Division of Endocrinology, 1994.
4. Cleveland Clinic Foundation, Division of Endocrinology, 1995.
5. University of Missouri, Kansas City, MO, School of Pharmacy, 1995.
6. Southern Illinois University Carbondale, IL, Department of Physiology, 1996.
7. University of Calgary, Calgary, Canada, Division of Endocrinology, 1997.
8. Brown University, Providence RI, Division of Endocrinology, 1997.
9. University of Arkansas, Little Rock, AK, Division of Endocrinology, 1998.
10. University of Arizona, Tucson, AZ. Division of Endocrinology, 1998.
11. University of Missouri, Columbia, MO, Division of Endocrinology, 1998.
12. Bombay University, Endocrinology and Diabetes Group, Bombay, India.
13. Tufts University, New England Medical Center, Boston, MA, 1998.
14. State University of New York at Stony Brook, Nassau County Medical Center, Department of Medicine, New York, NY, 1999.
15. University of Wisconsin, Division of Endocrinology, Madison, WI, 1999.
16. University of Southern Alabama, Division of Endocrinology, Mobile, AL, 2000.
17. University of Kansas School of Medicine, Wichita, KS. 2001.
18. Peking Union Medical College Hospital of the Chinese Academy of Medical Sciences, Beijing, China. 2001.
19. Harbin Medical University, Harbin , China, 2001.

Visiting Professorships (Cont'd) :

20. Sun Yat-sen University of Medical Sciences, Guangzhou, China, 2001.
21. Case Western Reserve University, Department of Internal Medicine/ Division of Endocrinology, Cleveland, Ohio, 2001.
22. Texas A & M University, Department of Internal Medicine, College Station/ Temple, Texas, 2001.
23. Texas Tech University, Department of Research and Development, El Paso, Texas 2002.
24. University of Wisconsin, Division of Endocrinology, Madison, Wisconsin, 2002.
25. Rush-Presbyterian-Saint Lukes Medical Center, Department of Internal Medicine, Chicago, IL., 2003.
26. Cleveland Clinic Foundation, Department of Endocrinology, Cleveland, OH. 2006.
27. University of Wisconsin, Division of Endocrinology, Madison, Wisconsin, 2006.
28. Saint Louis University, Department of Medicine, Saint Louis, MO., 2007.

Invited Presentations at National/International Symposia:

1. The role of micronutrients in aging. GRECC Nutrition Conference; Sepulveda, CA 1986.
2. Nutritional management of the elderly diabetic. American College of Physicians Intensive Course in Geriatric Medicine, Santa Monica, CA, 1987.
3. Aging blood brain barrier. Gerontologic Society of America Research Symposium, Washington, DC, 1987.
4. Theories of Aging. American College of Physicians Intensive Course in Geriatric Medicine, Beverly Hills, CA, 1988.
5. Sexual dysfunction in the Elderly. University of Arizona Postgraduate Course in Geriatrics. Tucson, AZ, 1988.
6. Management of Sexual dysfunction. American Geriatric Society Symposium on Sexuality, Chicago, IL, 1989.
7. Micronutrient in Diabetes. Arizona Geriatrics Society Meeting, Phoenix, AZ, 1989.
8. Endocrine changes of aging. University of Arizona Postgraduate Course in Geriatrics, Tucson, AZ, 1990.
9. Biology of Aging. University of Arizona Postgraduate Course in Geriatrics, Tucson, AZ, 1990.
10. Sexual dysfunction. University of Arizona Postgraduate Course in Internal Medicine, Tucson, AZ, 1990.
11. Thyroid disease in the elderly. Arizona Geriatrics Society meeting, Phoenix, AZ, 1991.
12. Diabetes-related changes in blood-brain barrier. Juvenile Diabetes Foundation Symposium, Washington, DC, 1991.
13. Diabetes in the Elderly. Annual Update of Diabetes, St. Louis, MO, 1991.
14. CNS effects of diabetes. NIH Symposium on Neurobiology, Bethesda, MD, 1992.
15. Insulin resistance. V.A. National Training Program, Symposium on Diabetes. St. Louis, MO, 1992.

Invited Presentations at National/International Symposia (cont'd):

16. Management of Dyslipidemia. V.A. National Training Program, Symposium on Diabetes. St. Louis, MO, 1993.
17. Theories of Aging. GRECC annual meeting, St. Louis, MO, 1993.
18. Micronutrient in Diabetes. Nutrition Symposium, Annual Meetings of The American Diabetes Association, Las Vegas, NV, 1993.
19. Diabetes and heart Disease. GRECC Annual Meeting, St. Louis, MO, 1995.
20. Diabetes in the Elderly. American Association of Osteopathic Instructors, Ft. Lauderdale, FL, 1995.
21. Thyroid hormone and aging. GRECC Annual Meeting, St. Louis, MO, 1996.
22. Micronutrients in Diabetes. American Diabetes Association Postgraduate Course. New York, NY, 1996.
23. Age-related changes in blood brain barrier. International Symposium of Neurobiology and Neuroendocrinology, Bregenz, Austria, 1996.
24. Diabetes in the Elderly. University of Rochester, Symposium on Diabetes, Rochester, NY, 1996.
25. Micronutrients in Diabetes. American Diabetes Association Postgraduate Course. Kingston, Jamaica, 1997.
26. Diabetes in the older adult. American Diabetes Association Postgraduate Course. New Orleans, LA, 1997.
27. Diabetes in the Elderly. American Association of Clinical Endocrinologists. Keystone, CO, 1997.
28. Nutritional Therapy of Diabetes. Case Western University Symposium on Clinical Advances in Geriatric Nutrition. Cleveland, OH, 1997.
29. Diabetes in older Adults. American Geriatrics Society Bayer Symposium on Diabetes. Atlanta, GA, 1997.
30. Drug Therapy of Diabetes. Annual meeting of Consultants For Long Term Care. Scottsdale, AZ, 1997.

Invited Presentations at National/International Symposia (cont'd):

31. The role of antioxidants in diabetes. Nutrition Symposium in Annual meetings of the American Diabetes Association, Boston, MA, 1997.
32. Diabetes in Older Adults. The Endocrine Society/NIA Symposium on Endocrinology and Aging. Minneapolis, MN, 1997.
33. Diabetes in Older Adults. Annual Meeting of The National Association of Directors of Nursing Homes, Austin, TX, 1997.
34. Pharmacokinetic Profile of Statins. St. Louis College of Pharmacy Symposium on Cholesterol, St. Louis, MO, 1997.
35. Glucotoxicity. Annual GRECC Meeting, St. Louis, MO, 1997.
36. Diabetes in Older Adults. St. Louis University Annual Symposium on Diabetes, St. Louis, MO, 1997.
37. Diabetes in Older Adults. American Dietetics Association Annual Meeting, Boston, MA, 1997.
38. Diabetes in the Elderly. State University of New York, Buffalo, NY, Symposium on Diabetes, Buffalo, NY, 1997.
39. Diabetes in Older Adult, Providence Endocrine Society Meeting, Providence, RI, 1997.
40. Drug Therapy of Type 2 Diabetes. Annual Meetings of Missouri Chapter of American College of Physician, Osage Beach, MO, 1997.
41. Diabetes In Older Adult, University of Arkansas Annual Symposium on Diabetes Little Rock, AK, 1998.
42. Diabetes in Older Adult. Southern Illinois University Annual Symposium on Diabetes, Springfield, IL, 1998.
43. Drug Therapy of Older Diabetic. NIH/American Diabetes Association Symposium on Type 2 diabetes in the elderly, Phoenix, AZ, 1998.
44. Drug Therapy of Diabetes in Older Adult. National Symposium on Diabetes in Elderly, Cancun, Mexico, 1998.
45. Thiazolidinediones:role in management of diabetes Washington University Symposium on Excellence in Diabetes care. St. Louis, MO, 1998.

Invited Presentations at National/International Symposia (cont'd):

46. Diabetes in older adult. Annual Meetings of the Association of Consultant Pharmacists. Orlando, FL, 1998.
47. Management of type 2 diabetes. Missouri Department of Health seminar. A look at diabetes care and coverage in Missouri. St. Louis, MO, 1999.
48. Sexual dysfunction in diabetes. The Annual meetings of the American Urological Association, Dallas, TX, 1999.
49. Hypothyroidism : a new look at an old problem. Wisconsin Endocrine Society, Madison, WI, 1999.
50. The treatment of postprandial hyperglycemia. University of Oklahoma Symposium: Diabetes in the New Millennium, Afton, OK, 1999.
51. New drug therapies for type 2 diabetes. University of Kansas Symposium; Demystifying drug therapy: New treatments for common problems, Wichita, KS, 1999.
52. New drug therapies for hyperlipidemia. University of Kansas Symposium; Demystifying drug therapy: New treatments for common problems. Wichita, KS, 1999.
53. Diabetes in older adults. American Diabetes Association Symposium, Springfield, IL, 2000.
54. Micronutrients in diabetes mellitus. The American Diabetes Association Annual meetings. Nutrition symposium, San Antonio, TX, 2000.
55. Obesity: A rational target for managing Type 2 diabetes. 30th International Symposium on Growth Hormone, Monte Carlo, Monaco, 2000.
56. The role of Thiazolidinediones in the treatment of diabetes. Annual meetings of Mississippi Academy of Family Medicine, Natchez, MI. 20001
57. Increased oxidative load in diabetes. American Diabetes Association Annual Meetings. Symposium on Diabetes and Antioxidants, Philadelphia, PA 2001.
58. Drug therapy of type 2 diabetes. Annual Meetings of Southern Illinois Medical Association, Bellville IL 2002.
59. Erectile dysfunction in aging men. Rocky mountain androgen conference, Banff, Alberta, Canada 2002.

Invited Presentations at National/International Symposia (cont'd):

60. Cardiovascular Disease in Diabetes. Annual Meeting of American Association of Osteopathic Family Physicians, Kansas City, MO. 2003.
61. New insulin therapies. Western Hormone Alliance Meetings. Kananaskis, Alberta, Canada, 2003.
62. The rationale for combination therapy in diabetes. Post Graduate Course of Mexican Diabetes Society, Mexico City, Mexico. 2003.
63. Diabetes in long term care. Annual Symposium of the California Association of Long Term Care Physicians, Los Angeles, CA 2004.
64. Towards a single tablet therapy of type 2 diabetes. Annual Meetings of Mexican Society of Internal Medicine, Veracruz, Mexico, 2004.
65. Nutritional therapy of diabetes. Annual Meetings of Mexican Society of Internal Medicine, Veracruz, Mexico, 2004.
66. Nutritional therapy of diabetes. Middle East Medical Assembly, Beirut, Lebanon, 2005.
67. Novel therapies for type 2 diabetes. Middle East Medical Assembly, Beirut, Lebanon, 2005.
68. New insulin therapies. Armenian Medical World Congress; San Francisco, CA. 2005
69. Antioxidants and diabetes. Nestle Nutrition Workshop, Hangzhou, China 2005.
70. The role of dietary and supplemental antioxidants in diabetes, The American Diabetes Association Annual Meetings, Washington, DC, 2006.
71. Diabetes in Klinefelter's syndrome; Causes and management. Seventh National conference of the American Association for Klinefelter syndrome; Saint Louis, MO 2006.
72. Obesity in the Elderly. First International Obesity Congress, Cleveland, OH, 2006.
73. ADA 2006 nutrition guidelines for people with diabetes. 17th Annual advances and controversies in clinical nutrition, Mayo College of Medicine; Savannah, GA, 2007.
74. Evidence based recommendation guidelines for the prevention and treatment of diabetes. International Armenian Medical Society meetings, Yerevan, Armenia June 2007.

Invited Presentations at National/International Symposia (cont'd):

75. Drug therapy of diabetes. International Armenian Medical Society meetings, Yerevan, Armenia, June 2007.
76. Obesity in the elderly. 8th Annual Conference in obesity, University of Southern Florida, Clearwater FL, 2007.
77. Dietary guidelines for diabetes. 8th Annual Conference in obesity, University of Southern Florida, Clearwater FL, 2007.
78. ADA nutrition guidelines for people with diabetes. 10th symposium of Diabetes and Endocrinology, Saint Louis University, Saint Louis, MO. 2008
79. Obesity in the elderly. 9th Annual Conference in obesity, University of Southern Florida, Orlando, FL, 2008.
80. Dietary guidelines for diabetes. 9th Annual Conference in obesity, University of Southern Florida, Orlando, FL, 2008.

Presentations at Scientific Meetings (Abstracts):

1. Cortas N, Mooradian A, Abras E, Walser M. The response to aldosterone of toad and turtle bladder is associated with changes in adenine nucleotide levels. *Kidney Int.* 21:270, 1982.
2. Frayha RA, Mooradian A, Abdelnoor A, Shamma'a M, Tamar H. Familial clustering of hepatitis B and multiple vasculopathies. *Arthritis Rheum.* 25 (suppl.) E2, 1982.
3. Suidan JS, Arngoat M, Zaydan R, Mooradian A, Cortas N. Relative estrogen excess in pregnancy-induced hypertension. *Clinical and Experimental Hypertension B1*:250, 1982.
4. Mooradian AD, Beyer HS, Ma KW, Kaiser F, Levine AS, Korchick W, Brown DM, Morley JE. The effect of aging, chronic renal failure and diabetes mellitus on human red and white cell calmodulin levels. *Endocrinology* 112:839A, 1983.
5. Shafer RB, Mooradian AD, Morley JE, Ma KW, Korchik W. Thyroid function in hemodialysis patients. *J. Nucl. Med.* 24:65, 1983.
6. Mooradian AD, Billington CJ, Nuttall FQ. Effect of co-ingestion of protein and glucose on the plasma glucose and insulin response to a glucose load. *J. Am. College of Nutr.* 2:102A, 1983.
7. Morley GK, Mooradian AD, Levine AS, Morley JE. Glucose infusion produces hyperalgesia in humans. *Clin. Res.* 31(2):392A, 1983.
8. Billington CJ, Mooradian AD, Duffy L, Lange P, Morley JE. Testosterone therapy in impotent patients with normal testosterone. *Clin Res.* 31(4):713A, 1983.
9. Mooradian AD, Schwartz HL, Oppenheimer JH. Free intranuclear and cytosolic T₃: Evidence for reduction in active transport of T₃ in the isolated hepatocyte as compared to in situ cells. Program of 60th Annual Meeting of American Thyroid Association, 1984.
10. Freake HC, Mooradian AD, Schwartz HL, Oppenheimer JH. Stereospecific transport of T₃ to cytoplasm and nucleus in GH cells. Program of the Annual Meeting of the Endocrine Society, 1985.
11. Mooradian AD, Mariash CN. Effect of insulin on gene expression in isolated hepatocyte cultures. Program of the Annual Meeting of the Endocrine Society, 1986.
12. Mooradian AD. Blood-brain barrier (BBB) choline transport in aged rats. 16th Annual Neuroscience Meeting, 409.10, 1986.

Presentations at Scientific Meetings (Abstracts) (cont'd):

13. Hartnell JM, Mooradian AD, Morley JE. DNA strand breaks in white blood cells of young, aged, and aged diabetic subjects. Clin. Res. 35(1):97A, 1987.
14. Osterweil D, Mooradian AD, Petrasek D, Morley JE. Diabetes mellitus in ambulatory elderly and nursing home patients: A survey of clinical characteristics and management. Clin. Res. 35(1):98A, 1987.
15. Korenman SG, Stanik-Davis S, Mooradian AD, Viosca S, Garza D. Evidence for a high prevalence of hypogonadotropic hypogonadism in sexually dysfunctional older men. Clin. Res. 35(1):182A, 1987.
16. Mooradian AD, Song MK. Using chamber studies of intestinal zinc transport rate in the aged rat. Clin. Res. 34(1):98A, 1987.
17. Mintz GA, Mooradian AD. Age-related morphologic changes in rat sublingual salivary glands. Fed. Proc. 46(3):1091, 1987.
18. Song MK, Mooradian AD. Effects of streptozotocin-induced diabetes, insulin and arachidonic acid on the intestinal zinc flux rate of rats. Fed. Proc. 46(3):599, 1987.
19. Flood JM, Morley JE, Mooradian AD. Learning and memory impairment in diabetic mice. Fed. Proc 46(3):1279, 1987.
20. Hartnell JM, Husain K, Mooradian AD, Morley JE. DNA strand breaks in white blood cells of young, aged and aged diabetic subjects. Clin. Res. 35:505A, 1987.
21. Mooradian, AD. Blood-brain barrier choline transport is reduced in diabetic rats. Clin. Res. 35:512A, 1987.
22. Mooradian, AD. The effect of ascorbate and dehydroascorbate on tissue uptake of glucose. Clin. Res. 35:512A, 1987.
23. Kaiser FE, Viosca SP, Morley JE, Mooradian AD, Davis SS, Korenman SG. Clinical and hormonal correlates of impotence in men over the age of 40. Clin. Res. 36(1):123A, 1988.
24. Korenman SG, Mooradian AD, Kaiser FE, Morley JE, Davis SS, Viosca SO. Treatment of vasculogenic sexual dysfunction with pentoxifylline. Clin. Res. 36(1):123A, 1988.

Presentations at Scientific Meetings (Abstracts) (cont'd):

25. Mooradian AD, Norman DC, Morley JE. The effect of zinc status on the immune function of diabetic rats. Clin. Res. (36):157A, 1988.
26. Kaiser FE, Viosca SP, Mooradian AD, Morley JE, Korenman SG. Impotence and aging: alterations in hormonal secretory patterns with age. Clin. Res. 21.
27. Mooradian, A.D. Blood-brain barrier choline transport is reduced in diabetic rats. Clin. Res. 35:512A, 36(1):96A, 1988.
28. Deebaj L, Song MK, Mooradian AD. The effect of dietary zinc content on micronutrient status of control and diabetic rats. Clin. Res. 36(1):166A, 1988.
29. Mooradian AD, Lieberman J. The serum angiotensin-converting enzyme (ACE) activity is decreased in the aged rat. The role of thyroidal status and food intake. Clin. Res. 36(1):96A, 1988.
30. Hartnell JH, Mooradian AD. Alkali-induced DNA unwinding is reduced in the liver and brain of aged rats. Clin. Res. 36(1):96A, 1988.
31. Mooradian AD, Song MK. Age-related alterations in intestinal calcium transport rate in rats. Clin. Res. 36(1):97A, 1988.
32. Deebaj L, Song MK, Mooradian AD. Levels and distribution of zinc, copper, magnesium, and calcium in control and diabetic rats fed different levels of dietary zinc. J. FASEB 2:A635, 1988.
33. Kaiser FE, Viosca SP, Mooradian AD, Morley JE, Korenman SG. Impotency and aging: Alterations in hormonal secretory patterns with age. Program of the Annual Meeting of the Endocrine Society, p. 215, 1988.
34. Mooradian AD. Effect of aging on stereospecific transport of 3-5-3' triiodothyronine (T₃) to cytoplasm and nucleus in rat liver. Program of the Annual Meeting of the Endocrine Society, p 217, 1988.
35. Hartnell JM, Storrie MC, Mooradian AD. Alkali-induced DNA unwinding is reduced in liver and brain of aged rats. Program of the Annual Meeting of the Gerontological Society of America, 1988.
36. Hartnell JM, Storrie MD, Mooradian AD. Alkali-induced DNA unwinding is reduced in diabetic rats and mice. Clin. Res. 37(1), 1989.

Presentations at Scientific Meetings (Abstracts) (cont'd):

37. Deebaj L, Song MK, Mooradian AD. The effect of dietary zinc content on the levels and distribution of copper and zinc in control and diabetic rats. American Chemical Society Symposium Copper Bioavailability and Metabolism. Dallas, Texas, 1989.
38. Clements N, Bluestein M, Reed R, Mooradian AD. Bacterial pneumonia in hospitalized young, old, and old-old patients: Comparison of presentation on admission. The Annual Meeting of the American Geriatrics Society, Boston, MA, 1989.
39. Mooradian AD, Deebaj L, Wegerhoff J, Wong NCW. Age-related alterations in the response of hepatic lipogenic enzymes to altered thyroid states. The Program of the Annual Meeting of the Endocrine Society, Seattle, WA, 1989.
40. Kershner Riggs G, Greiff V, Mooradian A, Meredith K, Reed R, Yochum K, Martinez C. Medical and psychosocial determinants of sexuality in elderly women. Program of the Annual Meeting of the Gerontological Society of America, 1989, p 48A.
41. Hartnell J, Mooradian AD. Alkali-induced DNA unwinding rate: A potential biomarker of aging. Program of the Annual Meeting of the Gerontological Society of America, 1989. Session #86.
42. Reed RL, Mooradian AD, Osterweil D, Clements N, Scuderi P. Lack of an association between the presence of tumor necrosis factor or interleukin-1 alpha in the blood and weight loss among elderly patients. Clin. Res. 38:82A, 1990.
43. Mooradian AD. The blood-brain barrier transport of glucose and butyrate is reduced in aged rats. Clin. Res. 38:81A, 1990.
44. Osterweil D, Mooradian AD, Mazorra L, Marshall CE. The effect of body weight loss on blood glucose levels in institutionalized diabetic patients. Program of the Annual Meeting of the American Geriatrics Society, 1990.
45. Habib M, Dickerson F, Mooradian AD. Increased in vivo ethane production in diabetes. Program of the Annual Meeting of the American Thoracic Society, 1990, Am. Rev. Resp. Dis. 141:A544, 1990.
46. Mooradian AD, Dickerson F, Habib M. The effect of age and food restriction on thyroid hormone-induced lipid peroxidation. Program of the Annual Meeting of the Endocrine Society. Atlanta, GA, 1990.

Presentations at Scientific Meetings (Abstracts) (cont'd):

47. Romney JS, Solyol MA, Deschamps BJ, Wanke IE, Carr FE, Mooradian AD, Wong NCW. L- triiodothyronine (T₃) regulates S11/Apolipoprotein A₁ (APO A₁) gene expression in rat liver and small intestine. Program of the Annual Meeting of the Endocrine Society, Atlanta, GA, 817 A, 1990.
48. Evans SE, Lee I, Yee D, Nixon B, Mooradian AD. The prevalence and nature of podiatric problems in elderly diabetic patients. Program of the Annual Meeting of the Gerontological Society of America, Boston, 1990.
49. Scuderi P, Reed R, Mooradian AD. In vitro interleukin-1 beta production is reduced in healthy elderly subjects. Program of the Annual Meeting of the Gerontological Society of America, Boston, 1990.
50. Reed RL, Perlmutter L, Yochum K, Meredith KE, Mooradian AD. The relationship between muscle mass and muscle strength in the elderly. Program of the Annual Meeting of The Gerontological Society of America, Boston, 1990.
51. Mooradian AD, Scarpace PJ. Adrenergic beta receptor activity of cerebral microvasculature is reduced in aged rats. Program of the Annual Meeting of the Gerontological Society of America, Boston, 1990.
52. Mooradian AD. Biomarkers of Aging. Program of the 26th Annual Meeting of the Society of Prospective Medicine, Mesa, 1990.
53. Reed RL, Osterweil D, Scuderi P, Mooradian AD. Elevated serum levels of tumor necrosis factor alpha predicts early mortality in elderly institutionalized patients. Clin. Res. 39:87A, 1991.
54. Mooradian AD. Age-related changes in protein profile of rat cerebral microvessels. Computer analysis of two-dimensional (2D) electrophoresis. Clin. Res. 39:87A, 1991.
55. Ruttinger AC, Reed R, DenHartog R, Perlmutter L, Yochum K, Mooradian AD. A comparison of hand held isometric strength measurement with isokinetic muscle strength measurement in the elderly. Program of the 48th Annual Meeting of the American Geriatrics Society. Chicago, 1991 p. 43.
56. Reed R, Yochum K, Perlmutter L, Mooradian AD. The level of physical exercise in healthy elderly population is not a predictor of body adiposity. Program of the 48th Annual Meeting of the American Geriatrics Society. Chicago, 1991, p. 76.

Presentations at Scientific Meetings (Abstracts) (cont'd):

57. Friedman D, Mooradian AD. The prevalence of overmedication with levothyroxine in ambulatory elderly patients. Program of the 48th Annual Meeting of the American Geriatrics Society. Chicago, 1991, p. 44.
58. Scuderi P, Reed R, Duerr M, Mooradian AD. The effect of age and diabetes mellitus on serum levels of lymphotoxin tumor necrosis factor beta (TNF β). Program of the Annual Meeting of the Gerontological Society of America. San Francisco, 1991; p 79.
59. Escobar G, Mooradian AD. Age-related differences in dietary regulation of lipogenic enzymes in rat liver and adipose tissue. Program of the Annual Meeting of the Gerontological Society of America. San Francisco, 1991, p 76.
60. Reed R, Kligman E, Yochum K, Perlmutter L, Meredith K, Mooradian AD. Predictors of the serum lipid profile in a healthy elderly population. Program of the Annual Meeting of the Gerontological Society of America. San Francisco, 1991, p 360.
61. Mooradian AD, Smith TL. The effect of age on lipid composition and order of rat cerebral microvessels. Program of the Annual Meeting of the Gerontological Society of America. San Francisco, 1991, P 279.
62. Mooradian AD, McCuskey RS. *In vivo* microscopic studies of age-related changes in the structure and the reactivity of cerebral microvessels. Clin Res. 40: 17A, 1992.
63. Mooradian AD, Scarpace PJ. Beta-adrenergic receptor activity of cerebral microvessels. Clin Res. 40:108A, 1992.
64. Mooradian AD, Scarpace PJ. Beta-adrenergic receptor activity of cerebral microvessels in experimental diabetes mellitus. 74th Annual Meeting of The Endocrine Society, 1992, p 92.
65. Mooradian AD, Grabau G, Uko-eninn A. In Situ quantitation of the age-related and diabetes-related changes in cerebral endothelial barrier antigen. Clin Res 41:9A, 1993.
66. Mooradian AD, Pinnaas JL, Lung CC, Yahya MD, Meredith K. Diabetes-related changes in the protein composition of rat cerebral microvessels. Clin Res 41:69A, 1993.
67. Meijer ME, Mooradian AD, Wong NCW. Aging alters the activity of specific transcription factors that regulate the thyroid hormone responsive S₁₄ gene. Clin Res 41:83A, 1993.
68. Reed R, Kligman E, Abyad A, Yochum K, Mooradian A. Predictors of the lipid profile in a healthy elderly population. Clin Res 41:103A, 1993.

Presentations at Scientific Meetings (Abstracts) (cont'd):

69. Giddings SS, Carnaghi LR, Mooradian AD. Effects of aging on gene expression in islet cells. 75th Annual Meeting of the Endocrine Society 1993, p. 368.
70. Wehmeier KR, Mooradian AD. Antioxidative potential of glucose and other simple carbohydrates. 75th Annual Meeting of the Endocrine Society 1993, P 424.
71. Friedman D, Reed R, Verdari R, Mooradian AD. Growth hormone therapy in the elderly. Annual Meeting of Am Geriatric Society 1993.
72. Fox-Robichaud A, Mooradian AD, Wong NCW. Senescence alters the activity of specific transcription factors that regulate the thyroid hormone responsive S₁₄ gene. Canadian Society of Clinical Investigation 1993.
73. Mooradian AD, Bastani B. The blood brain barrier proton translocating ATPases in diabetic and aged rats. Clin Res 42:13A, 1994.
74. Shah G, Byers P, Mahmoud S, Wong NC, Mooradian AD. Age-related changes in thyroid hormone induced hepatic Apo A₁ mRNA expression. 76th Annual Meeting of the Endocrine Society, 1994, P538.
75. Shah G, Mooradian AD. Age-related shortening of poly(A) tail of albumin mRNA. J. Invest. Med. 43:156A. 1995.
76. Shah G, Byers P, Mooradian AD. Identification of thyroid hormone responsive genes in adult rat cerebral tissue. 77th Annual Meeting of the Endocrine Society 1995. P2-447.
77. Shah GN, Mooradian AD. Differential display of thyroid hormone responsive mRNA in adult rat cerebral tissue. J. Invest. Med. 44:104A, 1996.
78. Shah, GN, Giddings SJ, Mooradian AD. Shortening of poly (A) tail of GLUT-1 mRNA in experimental diabetes mellitus. 10th International Congress of Endocrinology, 1996 P2-68.
79. Shah GN, Mooradian AD. Cloning of the cDNA and characterization of a thyroid hormone responsive protein in adult rat cerebrum. J. Invest Med. 1997.
80. Mooradian AD, Shah GN. Age-related changes in GLUT-1 mRNA structure and function. J. Invest. Med. 1997.

Presentations at Scientific Meetings (Abstracts) (cont'd):

81. Mooradian AD, Neumann C. PRECOSE resolution of optimal titration to enhance current therapies (PROTECT) study: Experience in the elderly. Annual Meeting of the American Geriatrics Society, Atlanta, GA, 1997.
82. Shah GN, Li J-P, Schneiderjohn P, Mooradian AD. Characterization of a thyroid hormone responsive protein in adult rat cerebrum. Annual Meeting of the Endocrine Society, Minneapolis, MN, 1997.
83. Shah GN, Mooradian AD. Cerebral tissue responsiveness to thyroid hormones in aging rats. J. Invest Med. 1998.
84. Shah GN, Mooradian AD. Cerebral tissue responsiveness to thyroid hormones in aging rats. Annual Meeting of the Endocrine Society, New Orleans, LA, 1998.
85. Freedman BI, Weurth JP, Cartwright K, Bain RP, Dippe S, Hershon K, Mooradian AD, Spinowitz BS. Design end baseline characteristics for the aminoguanidine clinical trial in overt type II diabetic nephropathy. (ACTION II). Annual Meeting of the American Diabetes Association, Chicago, IL, 1998.
86. Fujioka K, Weinstein SP, Rowe E, Mooradian AD. Sibutramine enhances weight loss and maintenance in obese hypertensive patients taking calcium channel blocker. European Congress on Obesity, Milan, Italy, 1999.
87. Chehade J, Kim J, Pinnas J, Mooradian AD. Malondialdehyde modification of rat cerebral proteins is reduced in experimental hypothyroidism. Annual Meetings of the Western Society of Clinical Investigation, Carmel, CA, 1999.
88. Thampy KJ, Haas MJ, Mooradian AD. Troglitazone activates acetyl-coenzyme A carboxylase at a post-translational level. The Annual Meeting of the Endocrine Society, San Diego, CA, 1999. p.464.
89. Thampy KJ, Haas MJ, Li J-P, Mooradian AD. Age-related changes in mRNA expression and activity of acetyl-coenzyme A carboxylase. The Annual Meeting of the Endocrine Society, San Diego, CA, 1999. p. 228.
90. Kim J, Chehade J, Pinnas JL, Mooradian AD. Malondialdehyde modification of rat cerebral proteins is reduced in experimental hypothyroidism. The Annual Meeting of the Endocrine Society, San Diego, CA., 1999. p. 207.
91. Haas MJ, Pun K, Reinacher D, Wong NCW, Mooradian AD. Fasting induces apolipoprotein A1 expression: The role of ketones. The Annual Meeting of the Endocrine Society. San Diego, CA., 1999. p.352.

Presentations at Scientific Meetings (Abstracts) (cont'd):

92. Fujioka K, McMahon FG, Mendel CM, Rowe E, Mooradian AD. Efficacy and safety of sibutramine in promoting and maintaining weight loss in obese African Americans and Caucasians with hypertension controlled by calcium channel blockers. Annual Meeting of the North American Association for the Study of Obesity (NAASO), Charleston, SC, 1999.
93. Mooradian AD, Weber MA, Shreve PE. Well-controlled hypertension in obese patients remains well-controlled during weight reduction on sibutramine treatment. The American Society of Hypertension Meetings, New York, NY, May, 2000. Published in Am. J. Hypertension, 13 (4, part 2), 2000, S128
94. Haas MJ, Li J-P, Mooradian AD. Thyroid hormone responsive protein (THRP) is not the rat homologue of c-Abl interactor protein (Abi-2). The Annual Meetings of the Endocrine Society, Toronto, Canada, 2000, p. 377.
95. Chehade JM, Hurd R, Punn K, Haas MJ, Mooradian AD. Age-related changes in plasma leptin binding activity in rats. A comparison of a simple acid-ethanol precipitation technique with column chromatography. The Annual Meetings of the Endocrine Society. Toronto, Canada, 2000, p.73.
96. Chehade JM, Mooradian AD. Serum leptin response to endogenous hyperinsulinemia in aging rats. The Annual Meetings of the Endocrine Society, Toronto, Canada, 2000, p.73.
97. Chehade JM, Silverberg AB, Kim J, Case C, Mooradian AD. The role of repeat fine-needle aspiration of thyroid nodules with benign cytologic findings. The Annual Meetings of the Endocrine Society, Toronto, Canada, 2000, p.592.
98. Haas MJ, Reinacher D, Wong NCW, Mooradian AD. Regulation of apolipoprotein A1 gene expression in acidosis: Requirement for transcriptional repressor. The Annual Meetings of the Endocrine Society, Toronto, Canada, 2000, p.113.
99. Haas MJ, Punn K, Reinacher D, Wong NCW, Mooradian AD. Effects of ketoacidosis on rat apolipoprotein A1 gene expression: A link with acidosis but not with ketones. The Annual Meetings of the Endocrine Society. Toronto, Canada, 2000, p.88.
100. Deleon MJ, Horani M, Haas MJ, Mooradian AD. Androgenic steroids downregulate apolipoprotein A1 promoter activity. The Annual Meetings of the Endocrine Society. Toronto, Canada, 2000, p.114.
101. Garber A, Mooradian A, Schneider S, Piper BA, Henry D. Metformin/glyburide tablets as first-line therapy in type 2 diabetes achieve glycemic control at lower final doses versus metformin or glyburide. The Annual Meetings of the American Association of Clinical Endocrinologists, Atlanta, GA, 2000.

Presentations at Scientific Meetings (Abstracts) (cont'd):

102. Donovan DS, Mooradian A, Schneider S, Piper BA, Henry D. Treatment of type 2 diabetes with metformin/glyburide tablets: An open label study, interim report. The Annual Meetings of the American Association of Clinical Endocrinologists, Atlanta, GA, 2000.
103. Poretsky L, Mooradian A, Buse J, Kyner J, Henry D. Effect of metformin/glyburide tablets on lactic acid in patients with type 2 diabetes. The Annual Meetings of the American Diabetes Association. San Antonio, TX, 2000.
104. Davidson J, Garber A, Mooradian A, Schneider S, Henry D. Metformin/glyburide tablets as first line treatment in type 2 diabetes: Distribution of HbA1c response. The Annual Meetings of the American Diabetes Association, San Antonio, TX, 2000.
105. Garber A, Mooradian A, Davidson J, Piper BA. Effect of metformin/glyburide tablets on HbA1c in first-line treatment of type 2 diabetes. The Annual Meetings of the American Diabetes Association, San Antonio, TX, 2000.
106. Donovan D, Mooradian A, Rosenstock J, Henry D. Effect of metformin/glyburide tablets on fasting glucose in type 2 diabetes. The Annual Meetings of the American Diabetes Association. San Antonio, TX, 2000.
107. Haas MJ, Kahn A, Li J, Wong NCW, Mooradian AD. Changes in intracellular PH and ion balance repress the apolipoprotein A1 gene promoter. The Annual Meetings of the Endocrine Society, Denver, CO. 2001.p.154.
108. Chehade JM, Haas MJ, Mooradian AD. Diabetes-related changes in rat cerebral occludin and zona occludens 1 (zo-1) expression . The Annual Meetings of the Endocrine Society, Denver,CO. 2001. p.223.
109. De Leon MS, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 (GLP-1) response to acarbose in elderly type 2 diabetic subjects. The Annual Meetings of the Endocrine Society, Denver, CO. 2001.p.415.
110. Haas MJ, Reinacher D, Wong NC, Mooradian AD. Basal apolipoprotein A1 gene expression in HepG2 cells: Requirement for MEK and protein kinase C. The Annual Meetings of the Endocrine Society, Denver, CO. 2001.p.539.
111. Haas MJ, Parseghian SA, Sajid RM, Mooradian AD. Effect of exogenous thyroid hormone responsive protein (THRP) expression on PC12 cell survival. The Annual Meetings of the Endocrine Society, San Francisco CA., 2002, page 201

Presentations at Scientific Meetings (Abstracts) (cont'd):

112. Haas MJ, Horani M, Plummer B, Li J-P, Wong NCW, Mooradian AD. Induction of the apolipoprotein AI promoter by insulin is repressed by saturated fatty acids. The Annual Meetings of the Endocrine Society, San Francisco CA., 2002, page584.
113. Haas MJ, Wadud K, Wong NCW, Mooradian AD. Antioxidants suppress the apolipoprotein AI (apoAI) promoter in the cultured hepatoma cell line, HepG2. The Annual Meetings of the Endocrine Society, San Francisco CA., 2002, page 262
114. Stewart G Albert SG, Mooradian AD, Cestia AT, Hackney LS Low-dose growth hormone (GH) as an adjuvant to life style modifications in the therapy of obesity. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
115. Haas MJ, Horani M, Wong NCW, Mooradian AD. Suppression of apolipoprotein AI gene expression by TNF α and IL-1 β . The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
116. Horani M, Gobal F, Haas MJ, Wong NCW, Mooradian AD. Cyclooxygenase (COX) inhibition is associated with downregulation of apolipoprotein AI (Apo-AI) promoter activity in cultured hepatoma cell line-HepG2. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
117. Haas MJ, Wong NCW, Mooradian AD. Induction of apolipoprotein AI gene expression by glucosamine. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
118. Haas MJ, Horani M, Wong NCW, Mooradian AD. Saturated fatty acids repress insulin-induction of the apolipoprotein AI gene promoter through inhibition of Sp1 activity. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
119. Myers SE, Albert SA, Haas MJ, Mooradian AD. Pubertal changes in serum leptin levels in type 1 diabetic adolescents: A controlled longitudinal study. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
120. Haas MJ, Parseghian SA, Sajid RM, Mooradian AD. Cell specificity of thyroid hormone responsive protein (THRP)–related cytotoxicity. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
121. Haas MJ, Fishman M, Mreyoud A, Mooradian AD. Thyroid hormone responsive protein (THRP) mediates thyroid hormone-induced cytotoxicity in primary neuronal cultures. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.

Presentations at Scientific Meetings (Abstracts) (cont'd):

122. Horani M, Haas MJ, Mooradian AD. Rapid adaptive changes in oxidative burst induced by high glucose in human umbilical vein endothelial cells (HUVEC). The Annual Meetings of the American Diabetes Association, New Orleans, LA, 2003.
123. Haas MJ, Mreyoud A, Fishman M, Mooradian AD. Microarray analysis of thyroid hormone induced changes in mRNA expression in the adult rat brain. The Annual Meetings of the Endocrine Society, Philadelphia, PA., 2003.
124. Haas MJ, Fishman M, Mreyoud A, Mooradian AD. Induction of thyroid hormone responsive protein and cell death by thyroid hormones in primary rat cerebral neurons. The Annual Meetings of the Endocrine Society, New Orleans, LA., 2004, p207.
125. Snyder PJ, Biller MK, Zagar A, Jackson I, Arafah BM, Nippoldt TB, Cook DM, Mooradian AD, Althouse SK, Chipman JJ, Hartman ML. Growth hormone (GH) replacement increases lumbar spine bone mineral density (BMD) in patients with adult onset GH deficiency. The Annual Meetings of the Endocrine Society, New Orleans, LA., 2004, p258.
126. Haas MJ, Horani M, Mooradian AD. Carvedilol suppresses hyperglycemia-induced superoxide formation and endothelial cell toxicity. The Annual Meetings of the Endocrine Society, New Orleans, LA., 2004, p318.
127. Haas MJ, Wadud K, Wong NCW, Mooradian AD. Differential effects of antioxidants on apolipoprotein AI gene expression in Hep G2 cells. The Annual Meetings of the Endocrine Society, New Orleans, LA., 2004, p350.
128. Wehmeier KW, Haas MJ, Mooradian AD. Apolipoprotein A-I promoter is down-regulated by vitamin D. Annual Meetings of the American Society of Bone and Mineral Metabolism, 2004.
129. Wehmeier KW, Beers AE, Haas MJ, Wong NCW, Mooradian AD. Vitamin D receptor antagonist ZK-191784 reverses inhibition of apo AI gene expression by $1\alpha, 25$ -dihydroxycholecalciferol. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p225.
130. Haas MJ, Wadud K, Mooradian AD. High-dose antioxidants down regulate apolipoprotein AI gene expression through a negative antioxidant response element within site A of the promoter. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p230.
131. Haas MJ, Feman SS, Mooradian AD. Prevention of endothelial barrier dysfunction of diabetes with rosuvastatin treatment. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p263.

Presentations at Scientific Meetings (Abstracts) (cont'd):

132. Haas MJ, Horani MH, Mooradian AD. Free-fatty acids selectively augment oxidative burst induced by high dextrose in human umbilical vein endothelial cells. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p263.
133. Beers AE, Haas MJ, Wong NCW, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor α : Roles for MEK/ERK and JNK signaling. The Annual Meetings of the Endocrine Society, San Diego, CA, 2005, p373.
134. Albert SG, Hasnain BI, Ritter DG, Joist H, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. The Annual Meetings of the American Diabetes Association, New San Diego, CA, 2005. 689 p in Diabetes 54 (suppl 1):A170.
135. Albert SG, Haas MJ, Mooradian AD. The effect of recombinant human growth hormone (rhGH) supplementation on vascular inflammatory markers in obese subjects. The Annual Meetings of the American Diabetes Association, New San Diego, CA, 2005. 1823 p in Diabetes 54 (suppl1):A438.
136. Wehmeier KW, Haas MJ, Beers AE, , Mooradian AD. Vitamin D receptor antagonist ZK 191784 augments apoA1 gene expression The Annual Meetings of the American Society for Bone and Mineral Research, Nashville, TN, 2005.
137. Haas, Michael J., Parseghian, S., Laz, B., Wong, N.C.W., and Mooradian, A.D. Inhibition of apolipoprotein AI gene expression by TNF α : requirement for JNK/c-jun activation. The Annual Meetings of the Endocrine Society, Boston, MA, 2006, Abstract # P1-455, p. 275.
138. Haas, M.J., and Mooradian, A.D. Statins ameliorate glomerular permeability changes in streptozotocin diabetic rats. The Annual Meetings of the Endocrine Society, Boston, MA, 2006, Abstract # P3-107, p. 663.
139. Parseghian S., Horain M.H., Haas, M.J., and Mooradian, A.D. Prevention of dextrose-induced endothelial cell dysfunction by statins through possible inhibition of superoxide formation. The Annual Meetings of the Endocrine Society, Boston, MA, 2006, Abstract # P3-412, p. 741.
140. Wehmeier, K.R., Haas, M.J., Beers, A., Wong, N.C.W., and Mooradian, A.D. Differential effects of vitamin D receptor ligands on apolipoprotein AI gene expression. The Annual Meetings of the Endocrine Society, Boston, MA, 2006, Abstract # P3-53, p. 649.
141. Mooradian AD, Albert SG, Lombardero M, Brooks MM, for the BARI 2D Trial Investigators. Anti-diabetes drug utilization in diabetic patients with coronary heart disease (CHD) enrolled in BARI 2D trial. The 67th Annual Meetings of the American Diabetes Association, Chicago, IL. Diabetes 56 (suppl 1); A549, 2007

Presentations at Scientific Meetings (Abstracts) (cont'd):

142. Albu JB, Lu J, Mooradian AD, Nesto RW, Porter M, Rana JS, Rogers WJ, Gottlieb S. Comparison of the association of body mass index vs. waist circumference with atherogenic risk factors in subjects with type 2 diabetes and documented coronary disease in the BARI2D trial. The 67th Annual Meetings of the American Diabetes Association, Chicago, IL. Diabetes 56 (suppl 1); A268, 2007
143. Ligaray K, Hachem S, Mazza A, Senkottaiyan N, Wong NCW, Mooradian AD, Haas MJ. Repression of apolipoprotein A-I gene expression by anandamide. The 67th Annual Meetings of the American Diabetes Association, Chicago, IL. Diabetes 56 (suppl 1); A56, 2007
144. Wehmeier KR, Hachem S, Ligaray K, Mazza A, Senkottaiyan N, Wong NCW, Mooradian AD, Haas MJ. Differential tissue-specific effects of vitamin D receptor ligands on apolipoprotein A-I gene expression. The Annual Meetings of the Endocrine Society, Toronto, Canada, 2007

Scientific Publications:

1. Frayha R.A., Mooradian A., Tabbara K.F. Transudative knee effusions in Milroy's disease. *J. Rheumatol.* 8:670-672, 1981.
2. Salti I.S., Mooradian A., Amiri Z., Khalil A. Hypopituitarism in a patient with idiopathic hypoparathyroidism. *Can. Med. Assoc. J.* 126:942-943, 1982.
3. Mooradian AD, Shammaa M. Liver cirrhosis in middle eastern population. A comparative study of clinical and histological features. *Arab J. Med.* 1(2):7-11, 1982.
4. Mooradian A., Ghusn H., Cortas N., Salti I. Serum hyperphosphatasia in pubertal gynecomastia: Case report and review of the literature. *Arab. J. Med.* 1(5):9-10, 1982.
5. Mooradian AD, Khouri JY, Arnaout MS, Cortas N. The effect of hemodialysis on serum alkaline phosphatase. *Arab J. Med.* 1(6):9-11, 1982.
6. Mooradian A., Budeir A., Faraidy Y. Cimetidine for treatment of alkalemia. *Can. Med. Assoc. J.* 127:462, 1982 (letter).
7. Mooradian A., Morley J.E., Simon G., Shafer R.B. Propranolol induced hyperthyroxinemia. *Arch. Int. Med.* 43:2193-2195, 1983.
8. Mooradian A.D., Allam C.K., Khalil M.F., Salti I., Salem Ph.A. Anaplastic transformation of thyroid cancer. *J. Surg. Oncology* 23:95-98, 1983.
9. Nuttall P.Q., Mooradian A.D., DeMarais R., Parker S. The glyceimic effect of different meals approximately isocaloric and similar in protein, carbohydrate and fat content as calculated using the A.D.A. exchange lists. *Diabetes Care* 6:432-435, 1983.
10. Mooradian A.D., Morley J.E., Ma K.W., Korchik W., Shafer R.B. Thyroid function in hemodialysis patients. *Eur. J. Nucl. Med.* 8:495-498, 1983.
11. Mooradian A.D., Morley G.K., McGeachie R., Lundgren S., Morley J.E. Spontaneous periodic hypothermia. *Neurology* 34:79-82, 1984.
12. Morley J.E., Levine A.S., Beyer H.S., Mooradian A.D., Kaiser F.E., Brown D.M. The effect of aging and diabetes mellitus on human red and white cell calmodulin levels. *Diabetes* 33:77-80, 1984.
13. Cortas N., Abras E., Arnaout M., Mooradian A., Maukasah S. Energetics of sodium transport in the urinary bladder of the toad: Effect of aldosterone and cyanide. *J. Clin. Invest.* 73:46-52, 1984.

Scientific Publications (cont'd):

14. Morley G.K., Mooradian A.D., Levine A.S., Morley J.E. Why is diabetic peripheral neuropathy painful? The effect of glucose on pain perception in humans. *Am. J. Med.* 77:79-82, 1984.
15. Mooradian A.D., Morley J.E., Levine A.S., Ma K.W., Korchik W., Beyer H.S., Kaiser F.E., Brown D.M. The effect of chronic renal failure on human red and white cell calmodulin levels. *J. Clin. Endocrinol. Metab.* 58:1010-1013, 1984.
16. Nuttall F.Q., Mooradian A.D., Gannon M.C., Billington C., Krezowski P. Effect of protein ingestion on the glucose and insulin response to a standardized oral glucose load. *Diabetes Care* 7:465-470, 1984.
17. Mooradian A.D., Morley J.E. Endocrine dysfunction in chronic renal failure. *Arch. Int. Med.* 144:351-353, 1984.
18. Mooradian A.D., Morley J.E., Levine A.S. The effect of aging on calcium-binding protein. *Geriatric Medicine Today*, 3:30-40, 1984.
19. Mooradian A.D., Shamma'a M., Salti I., Cortas N. Hypophyseal-gonadal dysfunction in men with non-alcoholic liver cirrhosis. *Andrologia* 17:72-79, 1985.
20. Mooradian A.D., Frayha R. Multiple vasculopathies and hepatitis B in a family. *Br. J. Rheumatol.* 24:19-23, 1985.
21. Mooradian A.D., Nuttall F.G. Insulin sensitivity in joggers: evaluation by mini-dose insulin infusion test. *Int. J. Sports Med.* 6:212-214, 1985.
22. Mooradian A.D., Morley J.E., Korchik W.P., Ma K.W., Hartfel M.A., Parsons J.A. Comparison between the bioactivity and immunoreactivity of serum prolactin in uremia. *Clin. Endocrinol.* 22:241-247, 1985.
23. Mooradian A.D., Schwartz H.L., Mariash C.N., Oppenheimer J.H. Transcellular and transnuclear transport of T₃ in isolated hepatocytes. *Endocrinology* 117:2449-2456, 1985.
24. Freake H.C., Mooradian A.D., Schwartz H.L., Oppenheimer J.H. Stereospecific transport of T₃ to cytoplasm and nucleus in GH1 cells. *Mol. Cell. Endocrinol.* 44:25-35, 1986.
25. Mooradian A.D., Morley J.E., Levine A.S., Prigge W.F., Gebhard R.L. Abnormal intestinal permeability to sugars in diabetes mellitus. *Diabetologia* 29:221-224, 1986.

Scientific Publications (cont'd):

26. Morley J.E., Silver A., Fiatarone M., Mooradian A.D. UCLA Grand Rounds: Nutrition and the Elderly. *J. Am. Geriatric Soc.* 34:823-832, 1986.
27. Mooradian A.D. Treatment of diabetes mellitus in the elderly. *Geriatric Medicine Today* 5:87-93, 1986.
28. Lum M.D., Mooradian A.D. Vitamin B12 deficiency in the elderly. *Geriatric Medicine Today* 5:87-93, 1986.
29. Regan J.J., Greenberg C.S., Mooradian A.D., Staley N., Nuttall F.Q. Reversible renal resistance to aldosterone associated with interstitial nephritis. *West. J. Med.* 146:742-745, 1987.
30. Mooradian A.D., Wynn E.M. The usefulness of pharmacokinetic prediction of the serum digoxin concentration in the elderly. *Arch. Int. Med.* 147:650-653, 1987.
31. Boghosian S.G., Mooradian A.D. Usefulness of routine preoperative chest roentgenograms in elderly patients. *J. Am. Geriatr. Soc.* 35:142-146, 1987.
32. Mooradian A.D. The effect of sulfonylurea on the in vivo tissue uptake of glucose in normal rats. *Diabetologia* 30:120-121, 1987.
33. Mooradian A.D., Mariash C.N. Effects of insulin and glucose on cultured rat hepatocyte gene expression. *Diabetes* 36:938-943, 1987.
34. Mooradian A.D. The effect of ascorbate and dehydroascorbate on tissue uptake of glucose. *Diabetes* 36:1001-1004, 1987.
35. Mooradian A.D. The blood-brain barrier choline transport is reduced in diabetic rats. *Diabetes* 36:1094-1097, 1987.
36. Tamai I.C., Sayers J., Mooradian A.D. Aminoglycoside therapy in elderly nursing home residents: outcome of therapy and toxicity. *Drug Intelligence and Clinical Pharmacy* 21:922-923, 1987.
37. Mooradian A.D., Song M.K. The intestinal zinc transport in aged rats. *Mech. Age. Develop.* 41:189-197, 1987.
38. Mooradian A.D., Morley J.E. Micronutrient status in diabetes mellitus. *Am. J. Clin. Nutr.* 45:877-895, 1987.

Scientific Publications (cont'd):

39. Mooradian A.D., Morley J.E., Korenman S.K. The biological actions of androgens. Endocrine Review 8:1-28, 1987.
40. Rosenthal M.J., Hartnell J.M., Morley J.E., Mooradian A.D., Fiatarone M., Kaiser F.K., Osterweil D. UCLA Grand Rounds: Diabetes in the elderly. J. Am. Geriatr. Soc. 35:435-447, 1987.
41. Morley J.E., Mooradian A.D., Rosenthal M.H., Kaiser F.E. Diabetes mellitus in the elderly: Is it different? Am. J. Med. 83:533-544, 1987.
42. Morley J.E., Korenman S.G., Mooradian A.D., Kaiser F.E. UCLA Grand Rounds: Male sexual dysfunction in the elderly. J. Am. Geriatr. Soc. 35:1014-1022, 1987.
43. Kavonian G.D., Wong N.C.W., Mooradian A.D. The unusual manifestations of hypothyroidism in an elderly patient. Geriatric Medicine Today 6(8):28-37, 1987.
44. Mooradian A.D. Nutritional status and dietary interventions in the elderly diabetic. Manual of Intensive Course in Geriatric Medicine, UCLA, pp 51-55, 1987.
45. Morley J.E., Mooradian A.D. Diabetes mellitus in nursing home patients. Second Season 2:1-3, 1987.
46. Mooradian A.D. Discrepancies between the calculated digoxin clearance and the serum digoxin level in elderly patients. (Letter) Arch. Intern. Med. 147:1853, 1987.
47. Mooradian A.D. The blood-brain barrier choline transport is reduced in aged rats. Brain Res. 440:328-332, 1988.
48. Kaiser F.E., Viosca S.P., Morley J.E., Mooradian A.D., Davis S.S., Korenman S.G. Impotence and aging: clinical and hormonal factors. J. Am. Geriatr. Soc. 36:511-519, 1988.
49. Mooradian A.D., Osterweil D., Petrusek D., Morley J.E. Diabetes mellitus in elderly nursing home patients: A survey of clinical characteristics and management. J. Am. Geriatr. Soc. 36:391-396, 1988.
50. Morley J.E., Korenman S.G., Kaiser F.E., Mooradian A.D., Viosca S.P. Relationship of penile brachial pressure index to myocardial infarction and cerebrovascular accidents in older males. Am. J. Med. 84:445-448, 1988.

Scientific Publications (cont'd):

51. Mooradian A.D., Pamplona D.G., Viosca S.P., Korenman S.G. The effect of free fatty acids on the bioavailability of plasma testosterone and dihydrotestosterone. *J. Steroid Biochem.* 29:369-370, 1988.
52. Song M.D., Mooradian A.D. Intestinal zinc transport: influence of streptozotocin-induced diabetes, insulin and arachidonic acid. *Life Sci.* 42:687-694, 1988.
53. Scarpace P.J., Mooradian A.D., Morley J.E. Age-associated decrease in beta-adrenergic receptors and adenylate cyclase activity in rat brown adipose tissue. *J. Gerontol.* 43:B65-B70, 1988.
54. Mintz G.A., Mooradian A.D. Age-related morphologic changes in rat sublingual salivary glands. *Gerodontology*, 6:137-144, 1988.
55. Mooradian A.D., Morley J.E., Scarpace P.J. The role of zinc status in altered cardiac adenylate cyclase activity in diabetic rats. *Acta Endocrinologica*, 119:174-180, 1988.
56. Mooradian A.D., Norman D.C., Morley J.E. The effect of zinc status on the immune function of diabetic rats. *Diabetologia*, 31:703-707, 1988.
57. Mooradian A.D., Perryman K., Fitten J., Kavonian G., Morley J.E. Cortical function in elderly non-insulin dependent diabetic patients: Behavioral and electrophysiological studies. *Arch. Int. Med.*, 148:2369-2372, 1988.
58. Mooradian D.G., Viosca S.P., Kaiser F.E., Morley J.E., Korenman S.G. Penile Raynaud's phenomenon: A possible cause of erectile failure. *Am. J. Med.* 85:748-750, 1988.
59. Mooradian A.D. The effect of aging on the blood-brain barrier. *Neurobiol. Aging* 9:31-39, 1988.
60. Mooradian A.D., Morley J.E., Korenman S.G. Endocrinology in Aging. *Disease-a-Month*, 34(7):398-461, 1988.
61. Morley J.E., Gorbien M.J., Mooradian A.D., Silver A.J., Brickman A.S., Kaiser F.E. UCLA Geriatric Grand Rounds: Osteoporosis. *J. Am. Geriatr. Soc.*, 36:845-859, 1988.
62. Mooradian A.D. Digitalis: An update of its clinical pharmacokinetics, therapeutic monitoring techniques, and treatment recommendations. *Clin. Pharmacokinetics*, 15:165-179, 1988.
63. Mooradian A.D. Tissue specificity of premature aging in diabetes mellitus: the role of cellular replicative capacity. *J. Am. Geriatr. Soc.*, 36:831-839, 1988.

Scientific Publications (cont'd):

64. Mooradian A.D. Diabetic complications of the central nervous system. *Endocrine Reviews*, 9:346-356, 1988.
65. Mooradian A.D., Nutritional modulation of life span and gene expression, pp 891-892. In Morley, J.E., Moderator, Nutrition in the elderly. *Ann. Int. Med.*, 109:890-904, 1988.
66. Mooradian A.D., Morley J.E. The Hypothalamus and the Pituitary Glands. In: Diagnosis and Pathology of Endocrine Diseases, Mendelsohn G. (ed.), J.B. Lippincott Co., Philadelphia, PA, 1988, pp 351-377.
67. Mooradian A.D., Song M.K. Age-related alterations in duodenal calcium transport rate in rats. *Mech. Ageing Dev.*, 47:221-227, 1989.
68. Mooradian A.D., Hernandez L., Tamai I., Marshall C. Variability of serum phenytoin levels in nursing home patients. *Arch. Int. Med.*, 149:890-892, 1989.
69. Mooradian A.D., Morley J.E., Kaiser F.E., Davis S.S., Viosca S.P., Korenman S.G. The role of biweekly intracavernous injection of papaverine in the treatment of erectile dysfunction. *West. J. Med.*, 151:515-517, 1989.
70. Tamai I., Strome L.S., Marshall C., Mooradian A.D. Drug-drug interactions in an academic nursing home. *Am. J. Hosp. Pharm.* 46:1567-1569, 1989.
71. Hartnell J.M., Morley J.E., Mooradian A.D. Alkali-induced white blood cell DNA unwinding rate is reduced in healthy elderly. A potential biomarker of aging. *J. Gerontol. Biol. Sci.* 44:B125-B130, 1989.
72. Hartnell J.M., Storrie M.D., Mooradian A.D. The tissue specificity of the age-related changes in alkali-induced DNA unwinding. *Mutation Research* 219:187-192, 1989.
73. Mooradian A.D., Scarpace P.J. The response of isoproterenol-stimulated adenylate cyclase activity after administration of L-triiodothyronine is reduced in aged rats. *Hormone and Metabolic Res* 21:638-639, 1989.
74. Mooradian A.D., Greiff V., Bressler R., Reed R., Marcus F. Digitalis in the elderly. *J. Am. Geriatr. Soc.* 37:873-882, 1989.
75. Morley J.E., Kaiser F.E., Mooradian A.D. Impotence. *Saudi Medical Journal*, 10:173-176, 1989.

Scientific Publications (cont'd):

76. Clements N., Mooradian A.D. The role of sodium fluoride in the treatment of osteoporosis. *Drug Therapy*, May: 69-78, 1989.
77. Mooradian A.D. Psychosocial aspects of diabetes in the elderly. *Diabetes Spectrum* 2:170, 1989.
78. Mooradian A.D. The role of gamma glutamyl transpeptidase in dementias. *Neurobiol. Aging* 10:109, 1989.
79. Mooradian A.D. Age-related differences in body weight loss in response to altered thyroidal status. *Experimental Gerontology* 25:29-35, 1990.
80. Mooradian A.D. Blood-brain transport of triiodothyronine is reduced in aged rats. *Mech. Ageing and Develop.* 52:141-147, 1990.
81. Mooradian A.D. Metabolic fuel and amino acid transport into brain in experimental hypothyroidism. *Acta Endocrinologica*, 122:156-162, 1990.
82. Korenman S.G., Viosca S.P., Kaiser F.E., Mooradian A.D., Morley J.E. Use of a vacuum tumescence device in the management of impotence. *J. Am. Geriatr. Soc.*, 38:217-221, 1990.
83. Hartnell J.M., Storrie M.D., Mooradian A.D. Tissue specificity of alkali-induced DNA unwinding rate in diabetes. *Diabetes* 39:345-353, 1990.
84. Mooradian A.D., Reed R.L., Osterweil D., Clements N., Scuderi P. Lack of an association between the presence of tumor necrosis factor or interleukin-1 alpha in the blood and weight loss among elderly patients. *J. Am. Geriatr. Soc.*, 38:397-401, 1990.
85. Habib M., Dickerson F., Mooradian A.D. Ethane production rate in vivo is reduced with dietary restriction. *J. Appl. Physiol.* 68:2588-2590, 1990.
86. Mooradian A.D. The hepatic transcellular transport of 3,5,3'-triiodothyronine is reduced in aged rats. *Biochim. Biophys. Acta* 1054:1-7, 1990.
87. Mooradian A.D., Reed R.L., Osterweil D., Shiffman R., Scuderi P. Decreased serum triiodothyronine (T₃) is associated with increased concentrations of tumor necrosis factor. *J. Clin. Endocrinol. Metab.* 71:1239-1242, 1990.
88. Mooradian A.D., Dickerson F., Smith T.L. Lipid order and composition of synaptic membranes in experimental diabetes mellitus. *Neurochem. Res.* 15:981-985, 1990.

Scientific Publications (cont'd):

89. Korenman S.G., Morley J.E., Mooradian A.D., Stanik Davis S., Kaiser F.E., Silver A.J., Viosca S.P., Garza D. Secondary hypogonadism in older men: its relation to impotence. *J. Clin. Endocrinol. Metab.* 71:963-969, 1990.
90. Mooradian A.D., Lieberman J. Age-related decrease in serum angiotensin converting enzyme activity: The role of thyroidal status and food intake. *J. Gerontol. Biol. Sci.* 45:B24-B27, 1990.
91. Flood J.F., Mooradian A.D., Morley J.E. Characteristics of learning and memory in streptozotocin-induced diabetic mice. *Diabetes* 39:1391-1398, 1990.
92. Mooradian A.D., Greiff V. Sexuality in older women. *Arch. Int. Med.* 150:1033-1038, 1990.
93. Reed R.L., Mooradian A.D. Drug therapy of elderly diabetic patient. *Drugs of Today* 26:109-123, 1990.
94. Mooradian A.D. Biomarkers of aging: Do we know what to look for. *J. Gerontol. Biol. Sci.* 45:B183-B186, 1990.
95. Mooradian A.D. Digoxin use in the elderly. *Drugs of Today* 26:381-388, 1990.
96. Mooradian A.D. Biomarkers of Aging (reprinted). *Proceedings of the 26th Annual Meeting of the Society of Prospective Medicine.* pp 2-5, 1990.
97. Mooradian A.D. Variability of serum phenytoin concentrations in nursing home patients. (letter) *Arch. Intern. Med.* 150:918-919, 1990.
98. Mooradian A.D. Phenytoin monitoring in nursing home patients (letter). *Arch. Intern. Med.* 150:1971-1974, 1990.
99. Mooradian A.D. Endocrine dysfunction due to renal disease. In: Principles and Practice of Endocrinology and Metabolism, K.L. Becker (ed.), Philadelphia, PA, J.B. Lippincott Co. 1990, pp 1533-1536.
100. Mooradian A.D., Kalis J, Neugent C. The nutritional status of ambulatory elderly Type II diabetic patients. *AGE* 13:87-89, 1990.
101. Mooradian A.D. Molecular Theories of Aging. In: Geriatric Nutrition. A Comprehensive Review. Morley, J.E., Glick Z., Rubenstein, L.Z. (eds.), New York, Raven Press 1990, pp 11-18.

Scientific Publications (cont'd):

102. Reed R.L., Mooradian A.D. Nutritional status and dietary management of elderly diabetic patient. *Clinics in Geriatric Medicine*, 6:883-901, 1990.
103. Mooradian A.D., Deebaj L., and N.C.W. Wong. Age-related alterations in the response of hepatic lipogenic enzymes to altered thyroid states in the rat. *J. Endocrinol* 128:79-84, 1991.
104. Mooradian A.D., Reed R.L., Meredith K., Scuderi P. Serum levels of tumor necrosis factor, IL-1 α and IL-1 β in diabetic patients. *Diabetes Care* 14:63-65, 1991.
105. Mooradian A.D., Morin A.M. Brain uptake of glucose in diabetes mellitus. The role of glucose transporters. *Am. J. Med. Sci.* 301:173-177, 1991.
106. Evans S.E., Lee I., Yee D., Nixon B., Mooradian A.D. The prevalence and nature of podiatric problems in elderly diabetic patients. *J. Am. Geriatr. Soc.* 39:241-245, 1991.
107. Mooradian A.D., Morin A., Clip L., Haspel H. Glucose transport is reduced in the blood-brain barrier of aged rats. *Brain Res.* 551: 145-149, 1991.
108. Mooradian A.D., Scarpace P.J. β -Adrenergic receptor activity of cerebral microvessels is reduced in aged rats. *Neurochem. Res.* 16:447-451, 1991.
109. Reed R.L., Perlmutter L., Yochum K., Meredith K.E., Mooradian A.D. The relationship between muscle mass and muscle strength in the elderly. *J Am Geriatr Soc* 39: 551-561, 1991.
110. Mooradian A.D. Increased serum conjugated dienes in elderly diabetic patients. *J Am Geriatr Soc* 39: 571-574, 1991.
111. Mooradian A.D., Reed R.L., Osterweil D., Scuderi P. Detectable serum levels of tumor necrosis factor alpha (TNF) may predict early mortality in elderly institutionalized patients. *J Am Geriatr Soc* 39:891-894, 1991.
112. Mooradian A.D., Reed R.L., Scuderi P. Serum levels of tumor necrosis factor alpha, interleukin-1 alpha and beta in healthy elderly subjects. *AGE* 14:61-64, 1991.
113. Mooradian A.D., Wong N.C.W. *Molecular Biology of Aging, Part I: An introduction to laboratory techniques.* *J. Am. Geriatr. Soc.* 39: 611-619, 1991.
114. Mooradian A.D., Wong N.C.W. *Molecular Biology of Aging, Part II: A synopsis of current research.* *J. Am. Geriatr. Soc.* 39: 717-723, 1991.

Scientific Publications (cont'd):

115. Reed R., Yochum K., Perlmutter L., Mooradian A.D. The interrelationship between physical exercise, muscle strength and body adiposity in healthy elderly population. *J Am Geriatr Soc*, 39:1189-1193, 1991.
116. Evans S.E., Mooradian A.D. Podiatric problems in elderly diabetic patients (letter). *J Am Geriatr Soc* 39: 946, 1991.
117. Reed R., Mooradian A.D. Treatment of diabetes mellitus in the elderly. *Am Family Physicians*. 44:915-924, 1991.
118. Mooradian A.D. Chronic illness and geriatric sexuality. *Clinics in Geriatric Medicine*, 7:113-130, 1991.
119. Friedman D., Reed R., Mooradian A.D. The prevalence of overmedication with levothyroxine in ambulatory elderly patients. *AGE*, 15:9-13, 1992.
120. Mooradian A.D.: Altered chromatin structure of cerebral nuclei in experimental diabetes mellitus. *Proc Soc of Exp Biol Med*, 199:282-286, 1992.
121. Mooradian A.D., Meredith K.E. The effect of age on protein composition of rat cerebral microvessels. *Neurochem Res* 17:665-670, 1992.
122. Mooradian A.D., Smith T.L. The effect of age on lipid composition and order of rat cerebral microvessels. *Neurochem Res*. 17:233-237, 1992.
123. Reed R.L., Kerwin J., Yoshimo M.T., Mooradian A.D. Undetectable serum levels of thyrotropin (TSH) in an older woman with secondary hypothyroidism. *J Am Geriatr Soc*, 40:68-70, 1992.
124. Mooradian A.D. The biological and functional definition of older patient. The role of biomarkers of aging. *Oncology* 6:(Suppl 2);39-44, 1992.
125. Reed R.L., Perlmutter L., Yochum R., Meredith K.E., Mooradian A.D. Form of presentation of data on muscle strength. *J Am Geriatr Soc*. 40:103, 1992.
126. Tchekmedyian N.S., Cella D.E., Mooradian A.D. Forward: Care of the older cancer patient. *Oncology* 6(Suppl 2):7-8, 1992.
127. Mooradian A.D. Management of diabetes in the elderly. In: Endocrinology and Metabolism in the Elderly, Morley, J.E. Korenman, S.G. (eds.), Blackwell Scientific Publications, Boston, 1992, pp 388-405.

Scientific Publications (cont'd):

128. Mooradian A.D. Water balance in the elderly. In: Endocrinology and Metabolism in the Elderly, Morley J.E., Korenman, S.G., (eds.), Blackwell Scientific Publications, Boston, 1992, pp 124-136.
129. Mooradian A.D. Geriatric Neuroendocrinology. In: Neuroendocrinology, C. B. Nemeroff (ed) CRC Press, Boca Raton, FL, 1992, pp. 541-562.
130. Reed R.L., Mooradian A.D. Diabetes mellitus in the elderly. In: Primary Care Geriatrics. R. Ham, P. Sloan (Eds). Mosby-Yearbook Inc. St. Louis, MO.1992, pp 549-560.
131. Mooradian A.D., Scarpace P.J. Beta-adrenergic receptor activity of cerebral microvessels in experimental diabetes mellitus. *Brain Res.* 583:155-160, 1992.
132. Mooradian A.D., McCuskey R.S. In vivo microscopic studies of age-related changes in the structure and the reactivity of cerebral microvessels. *Mech. Ageing Devel.* 64:247-254, 1992.
133. Mooradian A.D., Reed R.L., Duerr M.L., Valdez C., Scuderi P. The effect of age and diabetes mellitus on serum levels of lymphotoxin. *AGE* 15:95-99, 1992.
134. Romney J.S., Chan J., Carr F.E., Mooradian A.D., Wong N.C.W. Identification of the thyroid hormone responsive mRNA-S₁₁ as apolipoprotein A₁ mRNA and effects of the hormone on the promoter. *Mol Endocrinol* 6:943-950, 1992.
135. Mooradian A.D. Commentary. Use of glyburide vs glipizide in elderly non-insulin dependent diabetic patients. *Clinical Diabetes* Sept-Oct:73, 1992.
136. Mooradian A.D. Caring for the elderly nursing home patient with diabetes. A complex challenge to clinicians. *Diabetes Spectrum*, 5:318-322, 1992.
137. Campbell S., Mooradian A.D. Diabetes Mellitus. In *Geriatric Pharmacology* R. Bressler and M.K. Katz (eds.). McGraw-Hill, Inc. New York, NY, 1993, pp 409-425.
138. Nolan P., Mooradian A.D. Digoxin. In: *Geriatric Pharmacology*, R. Bressler and M.K. Katz (eds.), McGraw-Hill, Inc. New York, NY, 1993, pp. 151-163.
139. Mooradian A.D., Reed R.L. Diabetes mellitus in the elderly. In: *Cowdry's Practice of Geriatrics*. J.E. Morley (ed), F.A. Davis, Philadelphia (in press).
140. Mooradian A.D. Theories of Aging. In: *Cowdry's Practice of Geriatrics*. J.E. Morley (ed). F.A. Davis, Philadelphia (in press).

Scientific Publications (cont'd):

141. Mooradian A.D., Smith T.L. The effect of experimentally induced diabetes mellitus on the lipid order and composition of rat cerebral microvessels. *Neurosci Lett* 145:145-148, 1992.
142. Mooradian A.D. Mechanisms of age-related endocrine alterations in mammals. Part I *Drugs and Aging*. 3: 81-97, 1993.
143. Mooradian A.D. Mechanisms of age-related endocrine alterations in mammals. Part II *Drugs and Aging*. 3:131-146, 1993.
144. Reed RL, Hartog RD, Yochum K, Pearlmutter L, Ruttinger AC, Mooradian AD. A comparison of hand-held isometric strength measurement with isokinetic muscle strength measurement in the elderly. *J Am Geriatr Soc*. 41: 53-56, 1993.
145. Mooradian AD, Grabau G, Uko-eninn A. In-situ quantitative estimates of the age-related and diabetes-related changes in cerebral endothelial barrier antigen. *Brain Res* 309:41-44, 1993.
146. Mooradian AD, Smith TL. Membrane disordering effect of ethanol on cerebral microvessels of aged rats. *Neurobiol Aging*. 14:229-232, 1993.
147. Lung CC, Pinnas JL, Yahya D, Meinke GC, Mooradian AD. Malondialdehyde modified proteins and their antibodies in the plasma of control and streptozotocin induced diabetic rats. *Life Sci* 52:329-337, 1993.
148. McGinnis J, Bernbaum M, Brusca S, Plummer S, Albert SG, Mooradian AD. *Managing your diabetes a guide for individuals with diabetes mellitus*. St. Louis University Press, St. Louis, MO 1992.
149. Mooradian AD. Biomarkers of Aging. *Facts and Research in Gerontology* 8:80-86, 1994.
150. Mooradian AD, Siverly FD. Qualitative differences in the visual retention test performance of older non-insulin dependent diabetic patients. *AGE* 16:67-69, 1993.
151. Mooradian AD. Antioxidant properties of steroids. *J. of Steroid Biochem Mol Biol* 45:509-511, 1993.
152. Bernbaum M, Albert SG, McGinnis J, Brusca S, Miller D, Hoffman J, Kaiser FE, Mooradian AD. Laboratory assessment of glucose markers does not predict reliability of clinical performance. *Laboratory Medicine* 25:32-34, 1994.

Scientific Publications (cont'd):

153. Bernbaum M, Albert SG, Brusca S, McGinnis J, Miller D, Hoffman JW, Mooradian AD. Effectiveness of glucose monitoring systems modified for the visually impaired. *Diabetes Care* 16:1363-1366, 1993.
154. Bernbaum M, Albert SG, McGinnis J, Brusca S, Mooradian AD. The reliability of self blood glucose monitoring in elderly diabetic patients. *J. Am Geriatr Soc* 42:779-781, 1994.
155. Mooradian AD. Micronutrients in diabetes mellitus. In *drugs, diet and disease. Mechanistic Approaches to Diabetes*. Vol 2, 183-200, 1995.
156. Mooradian AD, Bastani B. Identification of proton-translocating adenosine triphosphatases in rat cerebral microvessels. *Brain Res.* 629:128-132, 1993.
157. Mooradian AD, Pinnas JL, Lung CC, Yahya MD, Meredith K. Diabetes-related changes in the protein composition of rat cerebral microvessels. *Neurochem Res.* 19:123-128, 1994.
158. Mooradian AD. *Biology of Aging*. In *Rehabilitation of the Aging and Elderly Patient*. G. Felsenthal, S.J. Garrison, F.U. Steinberg (eds). Baltimore, MD., Williams and Wilkins 1994 pp 3-10.
159. Mooradian AD, Scarpace PJ. 3,5,3'-L-triiodothyronine regulation of B-adrenergic receptor density and adenylyl cyclase activity in synaptosomal membranes of aged rats. *Neuroscience. Lett.* 161:101-104, 1993.
160. Mooradian AD, Habib MP, Dickerson F. Age-related changes in the effect of simple carbohydrates, casein hydrolysate and a lipid test meal on ethane exhalation rate. *J. Appl. Physiol* 76:1119-1122, 1994.
161. Wehmeir KR, Mooradian AD. Autooxidative and antioxidative potential of simple carbohydrate. *Free Radical in Biol Med.* 17:83-86, 1994.
162. Mooradian AD, Failla M, Hoogwerf B, Isaac R, Maryniuk M, Wylie-Rosett J. Selected vitamins and minerals in diabetes. *Diabetes Care* 17:4645-479, 1994.
163. Mooradian A.D. Behavioral effects of noninsulin-dependent diabetes mellitus in the elderly. *Neurobiol Aging.* 15:565-567, 1994.
164. Habib MP, Dickerson F, Mooradian AD. Effect of diabetes, insulin and glucose load on lipid peroxidation in the rat. *Metabolism* 43:1442-1445, 1994.

Scientific Publications (cont'd):

165. Mooradian AD, Habib MP, Dickerson F, Yetskievych T. The effect of age on L-3, 5, 3', triiodothyronine induced ethane exhalation. *J. Appl Physiol.* 77:160-164, 1994.
166. Mooradian AD. Potential mechanisms of the age-related changes in the blood-brain barrier. *Neurobiol Aging* 15:751-755, 1994.
167. Mooradian AD. The aging blood-brain barrier commentary. *Neurobiol Aging* 15:765,1994.
168. Mooradian AD. Diabetes in the elderly editorial. *Diabetes Spectrum* 7:358-383, 1994.
169. Mooradian AD, Wong NCW. Age-related changes in thyroid hormone action. *Eu. J. Endocrinol* 131:451-461, 1994.
170. Mooradian AD, Grabau G, Bastani B. Adenosine triphosphatases of rat cerebral microvessels. Effect of age and diabetes mellitus. *Life Sci.* 55:1261-1265, 1994.
171. Mooradian AD, Shah G, Lung CC, Mahmoud S, Pinnas J. Age-related changes in tissue distribution of malondialdehyde modified proteins. *Life Sci.* 55:1561-1566, 1994.
172. Shah G, Pinnas JL, Lung CC, Mahmoud S, Mooradian AD. Tissue-specific distribution of malondialdehyde modified proteins in diabetes mellitus. *Life Sci.* 55:1343-1349, 1994.
173. Mooradian AD. Normal age-related changes in thyroid hormone economy. *Clinics in Geriatric Medicine* 11:159-169, 1995.
174. Mooradian AD, Fox-Robichaud A, Meijer ME, Wong NCW. Relationship between transcription factors and S₁₄ gene expression in response to thyroid hormone and age. *Proc. Soc. Exp. Biol. Med.* 207:97-101, 1994.
175. Mooradian AD, Uko-eninn A. Age-related changes in the antioxidative potential of cerebral microvessels. *Brain Res.* 671:159-163, 1995.
176. Mooradian AD. The antioxidative potential of cerebral microvessels in experimental diabetes mellitus. *Brain Res.* 671:164-169, 1995.
177. Mooradian AD. Endocrine dysfunction due to renal disease. In: *Principles and Practice of Endocrinology and Metabolism.* K.L. Becker (ed.) Philadelphia, PA . J.B. Lippincott Co. pp 1759-1762, 1995.

Scientific Publications (cont'd):

178. Giddings SJ, Carnaghi LR, Mooradian AD. Age-related changes in pancreatic islet cell gene expression. *Metabolism* 44:320-324, 1995.
179. Mooradian AD, Lung CC, Pinnas JL. Cholesterol enriched diet enhances malondialdehyde modification of proteins in cerebral microvessels of rabbits. *Neurosci Lett.* 185:211-213, 1995.
180. Mooradian AD (ed) *Internist's Handbook of Endocrinology, Diabetes and Metabolism.* St. Louis University Press, St. Louis, Mo 1995.
181. Shah NG, Wong NCW, Mooradian AD. Age-related changes in apolipoprotein A₁ expression. *Biochem Biophys Acta* 1259:277-282, 1995.
182. Shah GN, Mooradian AD. Age-related shortening of Poly (A) tail of albumin mRNA. *Arch of Biochemistry Biophysics* 324:105-110, 1995.
183. Bernbaum M, Albert SG, Miller D, Hoffmann JW, Mooradian AD. Reliability of Diascan partner glucose monitor for visually impaired people. *Diabetes Spectrum* 8:322-324, 1995.
184. Mooradian AD. Diabetes in the elderly: Studies dispel common misconceptions. *Clev. Clin J. of Med* 62:1-3, 1995.
185. Mooradian AD. Theories of Aging. In *Geriatric Nutrition. A Comprehensive Review.* Morley J.E., Glick Z., Rubenstein L.Z. (eds) New York Raven Press. 1995; pp 5-13.
186. Bernbaum M, Albert SG, Miller D, Stich T, Hoffmann JW, Mooradian AD. Alternative blood glucose monitoring strips for the One Touch System. *Laboratory Medicine* 27:404-407, 1996.
187. Mooradian AD, Albert SG, Bernbaum M, Plummer S. The effect of glipizide GITS on islet cell hormonal responses to a test meal in NIDDM. *Diabetes Care* 19:883-884, 1996.
188. Mooradian AD. Glycosylation enhances malondialdehyde binding to proteins. *Free Radical Biol. Med.* 21:699-701, 1996.
189. Mooradian AD. Drug therapy of non-insulin dependent diabetes mellitus in the elderly. *Drugs* 51:931-941, 1996.
190. Song MK, Rosenthal MJ, Kang KW, Adham NF, Mooradian AD, Arment ME. Animal prostate extract ancliorates diabetic symptoms by stimulating intestinal zinc absorption in rats. *Diabetes Research* 31:157-170, 1996.

Scientific Publications (cont'd):

191. Mooradian AD, Wong NCW, Shah GN. Age-related changes in the responsiveness of apolipoprotein A₁ to thyroid hormone. *Am J Physiol.* 271:R1602-R1607, 1996.
192. Thurman J, Mooradian AD. How to handle elderly patients. *Medical Interface* Jan:1997, pp 11-12.
193. Mooradian AD. NIDDM in the elderly. *Drug Therapy for blood glucose control. Medical Progress* Oct:39-44, 1996.
194. Nowak FV, Mooradian AD. Endocrine Function and Dysfunction with age. *Encyclopedia of Gerontology.* Academic Press, Inc., San Diego, CA. Vol. 1, 1996, pp 447-491.
195. Reed RL, Mooradian AD. Diabetes mellitus. In *Primary Care Geriatrics. A case based approach.* 3rd edition R.J. Ham, P.D. Sloan, (Eds) Mosby-Yearbook Inc., St. Louis, MO 1997 pp 440-4476.
196. Nowak FV, Mooradian AD. Thyroid hormone action and aging. In *Geriatric Medicine in the 21st Century: Basic Science Contributions to Clinical Care.* J.E. Morley, H.J. Armbrecht, R.M. Coe. (eds) Springer Verlag, New York, 1997.
197. Mooradian AD, Girgis WE, Shah GN. Thyroid hormone-induced GLUT-1 expression in rat cerebral tissue: effect of age. *Brain Res.* 747:144-146, 1997.
198. Shah GN, Giddings SJ, Mooradian AD. Shortening of poly (A) tail of glucose transporter-one mRNA in experimental diabetes mellitus. *Brain Res.* 754:213-220, 1997.
199. Anderson JH Jr and the Multicenter Insulin Lispro Study Group. Mealtime treatment with insulin analog improves postprandial hyperglycemia and hypoglycemia in patients with non-insulin-dependent diabetes mellitus. *Arch Intern Med.* 157: 1249-1255, 1997.
200. Mooradian AD. Are micronutrients important in diabetes management? *West Indian Med. J.* 46(suppl. 1):21, Feb.-Mar, 1997.
201. Mooradian AD. Central nervous system complications of diabetes mellitus. A perspective from the blood-brain barrier. *Brain Res. Rev.* 23:210-218, 1997.
202. Mooradian AD. Pathophysiology of central nervous system disorders in diabetes. *Clin. Neurosci* 4:322-326, 1997.
203. Mooradian AD, Nowak FV. Diabetes mellitus and heart disease. In *Cardiovascular Disease in Older Persons.* F.E. Kaiser, J. E. Morley, R. M. Coe (ed) Springer Verlag, New York, 1997, 53-72.

Scientific Publications (cont'd):

204. Shah GN, Mooradian AD. Age-related changes in the blood brain barrier. *Exp. Gerontol.* 32:501-519, 1997.
205. Thurman J, Mooradian AD. Vitamin supplementation therapy in the elderly. *Drugs and Aging.* 11:433-449,1997.
206. Mooradian AD, Wong NCW, Shah GN. Apolipoprotein A1 expression in young and aged rats is modulated by dietary carbohydrates. *Metabolism* 46:1132-1136,1997.
207. Enalapril-Felodipine ER Factorial Study Group. Combined enalapril and felodipine extended release (ER) for systemic hypertension. *Am J Cardiol* 79:431-435, 1997.
208. Mooradian AD, Chung HC, Shah GN. GLUT-1 expression in the cerebra of patients with Alzheimer's disease. *Neurobiol Aging* ,18: 469-474, 1997.
209. Mooradian AD, Shah GN. Age-related changes in glucose transporter-one (GLUT-1) mRNA structure and function. *Proc. Soc. Exp. Biol. Med.* 216:380-385, 1997.
210. Mooradian AD, Bastani B. The effect of metabolic acidosis and alkalosis on the H⁺-ATPase of rat cerebral microvessels. *Life Sci* 61:2247-2253, 1997.
211. Shah GN, Li JP, Schneiderjohn P, Mooradian AD. Cloning and characterization of a complementary DNA for a thyroid hormone responsive protein in mature rat cerebral tissue. *Biochemical J.* 327:617-623, 1997.
212. Testa MA, Simonson DC on behalf of Glipizide GITS Study Investigators. Health economic benefits and quality of life during improved glycemic control in patients with type 2 diabetes mellitus. A randomized, controlled, double-blind trial. *JAMA* 280: 1490-1496, 1998.
213. Silverberg AB, Mooradian AD. The Thyroid and Aging. *Interdisciplinary Topics In Aging, Functional Endocrinology of Ageing* 29 :27-43,1998.
214. Reed RL, Mooradian AD. Management of diabetes mellitus in the nursing home. *The Annals of Long Term Care* 6:100-107,1998.
215. Yu Z, Gupta SK, Hwang SS, Kipnes MB, Mooradian AD, Snyder PJ, Atkinson LE. Testosterone pharmacokinetics after application of an investigational transdermal system in hypogonadal men. *J. Clin. Pharmacol.* 37:1139-1145, 1997.

Scientific Publications (cont'd):

216. Johnston PS, Feig PU, Coniff RF, Krol A, Kelley DE, Mooradian AD. Chronic treatment of African-American type 2 diabetic patients with alpha-glucosidase inhibition. *Diabetes Care* 21:416-422, 1998.
217. Mooradian AD (ed), *Internist's Handbook of Endocrinology, Diabetes and Metabolism*. St. Louis University Press, 1998.
218. Murao K, Wada Y, Nakamura T, Taylor AH, Mooradian AD, Wong NCW. Effects of glucose and insulin on rat apolipoprotein A1 gene expression. *J. Biol. Chem.* 273:18959-18965, 1998.
219. Shah GN, Li J, Mooradian AD. Novel translational repressor (NAT-1) expression is modified by thyroid state and age in brain and liver. *Eu. J. Endocrinology* 139: 649-653, 1998.
220. Mooradian AD, McLaughlin S, Boyer C, Winter J. Diabetes care for the older adult. *Diabetes Spectrum* 12:70-77, 1999.
221. Mooradian AD, Thurman JE. Drug therapy of postprandial hyperglycemia *Drugs* 57:19-29, 1999.
222. Mooradian AD, Li J, Shah GN. Age-related changes in thyroid hormone responsiveness protein (THRP) expression in cerebral tissue of rats. *Brain Res.* 793:302-304, 1998.
223. Thurman JE, Mooradian AD. Starving for sugar. *Patient Care* 32:142-143, 1998.
224. Mooradian AD. Repaglanide; A viewpoint. *Drugs and Aging*. 13:181-182, 1998.
225. Mooradian AD, Albert SG. The age-related changes in lipogenic enzymes: the role of dietary factors and thyroid hormone responsiveness. *Mechanism of Ageing and Development* 108: 139-149, 1999.
226. Chehade J, Kim J, Pinnas J, Mooradian AD. Malondialdehyde binding of rat cerebral proteins is reduced in experimental hypothyroidism. *Brain Research* 829:202-203, 1999.
227. Mooradian AD. Rosiglitazone. A viewpoint. *Drugs* 57:931, 1999.
228. Mooradian AD, Chehade J, Kim J. Age-related changes in thyroid hormone effects on glucose transporter isoforms of rat heart. *Life Sciences* 65:981-989, 1999.
229. Freedman BI, Wuerth J-P, Cartwright K, Bain R, Dippe S, Hershon K, Mooradian AD, Spinowitz B. Design and baseline characteristics for the aminoguanidine clinical trial in overt type 2 diabetic nephropathy (ACTION II). *Controlled Clinical Trials.* 20:493-510, 1999.

Scientific Publications (cont'd):

230. Chehade J, Kim J, Pinnas JL, Mooradian AD. Age-related changes in the thyroid hormone effects on malondialdehyde modified proteins in the rat heart. *Proc.Soc.Exp.Biol.Med.* 222:59-64, 1999.
231. Mooradian AD, Chehade J. Implications of the UK Prospective Diabetes Study: Questions answered and issues remaining. *Drugs and Ageing* 16:159-164, 2000.
232. Chehade J, Mooradian AD. Drug therapy of diabetes in old age. In *Diabetes in Old Age-2nd edition*, AJ Sinclair, P Finucane, (eds) 2000.
233. Mooradian AD, Albert SG, Wittry S, Chehade J, Kim J, Bellrichard B. Dose-response profile of acarbose in older subjects with Type 2 diabetes. *Am. J. Med. Sci.* 319:334-337, 2000.
234. Chehade J, Mooradian AD. A rational approach to drug therapy of Type 2 diabetes mellitus. *Drugs* 60: 95-113, 2000.
235. Mooradian AD, Chehade J, Hurd R, Haas MJ. Monosaccharide enriched diets cause hyperleptinemia without hypophagia. *Nutrition* 16: 439-441, 2000.
236. Kamel HK, Mooradian AD, Mir T. Biological theories of aging. In: *Contemporary Endocrinology: Endocrinology of Aging*. J.E. Morley and L. van den Berg (eds), Humana Press Inc., Totowa, NJ. pp:1-9, 2000.
237. Mooradian AD, Li JP. The effect of amitriptyline on the messenger RNA of thyroid hormone responsive genes in rat cerebral tissue. *Experimental Brain Research* 132:276-278, 2000.
238. McMahon FG, Fujioka K, Singh K, Mendel CM, Rowe E, Rolston K, Johnson F, Mooradian AD. Efficacy and safety of sibutramine in obese White and African American patients with hypertension: A one-year, double blind, placebo-controlled, multicenter trial. *Archives of Internal Medicine* 160: 2185-2191, 2000.
239. Mooradian AD, Chehade JM. Serum leptin response to endogenous hyperinsulinemia in aging rats. *Mechanisms of Ageing and Development*. 115:101-106, 2000.
240. Haas MJ, Pun K, Reinacher D, Wong NCW, Mooradian AD. Effects of ketoacidosis on rat apolipoprotein A1 gene expression: A link with acidosis but not with ketones. *J. Molecular Endocrinology* 25: 129-139, 2000.
241. Mooradian AD, Thurman J. Glucotoxicity: Potential mechanisms. *Clinics in Geriatric Medicine* 15:255-263, 1999.

Scientific Publications (cont'd):

242. Thurman JE, Mooradian AD. Age-related carbohydrate intolerance. In *The Science of Geriatrics. Facts, Research and Intervention in Geriatrics Series*. J.E. Morley, H.S. Armbrecht, R.M. Coe, B. Vellas, eds., Serdi Publisher .Paris, 2000. Vol. 2, pp409-417.
243. Todd CC, Mooradian AD. Thyroid changes with aging. In *The Science of Geriatrics . Facts, Research and Intervention in Geriatrics*. J.E. Morley, H.J. Armbrecht, R.M. Coe, B. Vellas, eds., Serdi Publisher, Paris, 2000, vol. 1, pp273-281.
244. Korenman SG, Mooradian AD, Hendrick V. Changes in men as they age: The menopause. In: *Menopause. Biology and Pathobiology*. RA Lobo, J Kelsey, and R Marcus (eds), Academic Press, San Diego, CA, 2000, pp. 111-133.
245. Mooradian AD, Hurd R, Chehade J, Pun K, Haas M. Age-related changes in plasma leptin binding activity in rats. A comparison of a simple acid-ethanol precipitation technique with column chromatography. *Proc. Soc. Exp. Biol. Med.* 224: 273-277, 2000.
246. Apfel SC et al for the rhNGF Clinical Investigator Group. Efficacy and safety of recombinant human nerve growth factor in patients with diabetic polyneuropathy. A randomized controlled trial. *JAMA* 284: 2215-2221, 2000.
247. Haas MJ, Reinacher D, Pun K, Wong NCW, Mooradian AD. Induction of the apolipoprotein A1 gene by fasting: A relationship with ketosis but not with ketone bodies. *Metabolism* 49:1572-1578, 2000.
248. Mooradian AD, Chehade J. Implications of the UK Prospective Diabetes Study. Questions answered and issues remaining. In *Drug Treatment of Type 2 Diabetes*. Andrew J. Krentz (ed.) Adis Int. Ltd. 2000, pp 23-29.
249. Kim J, Chehade J, Pinnas JL, Mooradian AD. Effect of select antioxidants on malondialdehyde-modification of proteins. *Nutrition* 16: 1079-1081, 2000.
250. Thampy KG, Haas MJ, Mooradian AD. Age-related changes in rat hepatic acetyl-coenzyme A carboxylase. *Proc. Soc. Exp. Biol. Med.* 225: 123-127, 2000.
251. Fujioka K and the Sibutramine/Diabetes Clinical Study Group. Weight loss with sibutramine improves glycaemic control and other metabolic parameters in obese patients with type 2 diabetes mellitus. *Diabetes, Obesity and Metabolism* 2: 175-187, 2000.
252. Kim J, Mooradian AD. Hyperinsulinemic hypoglycemia associated with possible hypopituitarism in a patient with acquired immune deficiency syndrome. *Endocrine Practice* 6: 453-455, 2000.

Scientific Publications (cont'd):

253. Thampy GK, Haas MJ, Mooradian AD. Troglitazone stimulates acetyl-Co A carboxylase activity through a post-translational mechanism. *Life Sci.* 68: 699-708, 2000.
254. Mooradian AD, Reinacher D, Li JP, Pinnas JL. Malondialdehyde-modification of proteins in vitro is enhanced in the presence of acetaldehyde. *Nutrition* 17: 619-622, 2001.
255. Rosenstock J et al for the HOE901 Study Group. Basal insulin therapy in type 2 diabetes. *Diabetes Care* 24: 631-636, 2001.
256. Haas MJ, Reinacher D, Li JP, Wong NCW, Mooradian AD. Regulation of ApoA1 gene expression with acidosis: Requirement for a transcriptional repressor. *J. Mol. Endocrinol.* 27:43-57, 2001.
257. Chehade JM, Silverberg AS, Kim JH, Case CC, Mooradian AD. The role of repeat fine needle aspiration of thyroid nodules with benign cytology. *Endocrine Practice.* 7:237-243, 2001.
258. Mooradian AD. Endocrine dysfunction due to renal disease. In: Principles and Practice of Endocrinology and Metabolism. 3rd edition, KL Becker , Editor; Lippincot, Williams and Wilkins, Philadelphia, 2001, pp1908-1911.
259. Mooradian AD, Chehade JM, Thurman JE. The role of thiazolidenediones in the treatment of type 2 diabetes. *Treatments in Endocrinology* 1:13-20, 2002.
260. Brown WV et al for the Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: A randomized, double-blind, 52 week trial. *Am. Heart J.* 144:1036-1043, 2002.
261. Deleon MJ, Horani, MH, Haas MJ, Wong NCW, Mooradian AD. Effects of dehydroepiandrosterone (DHEA) on rat apolipoprotein A1 gene expression in the human hepatoma cell line, HepG2. *Metabolism* 56:101-106, 2002..
262. Reed RL, Mooradian AD. Diabetes Mellitus in Primary Care Geriatrics. A Case Based Approach. RJ Ham, P.D.Sloan, G.A.Warshaw (eds), Fourth edition , Mosby Inc., St. Louis, 2002, pp 507-515.
263. Mooradian AD. Obesity: A rational target for managing diabetes mellitus. *Growth Hormone & IGF research (suppl. A)* :S1-S5, 2001.
264. Deleon MJ, Chandurkar V, Albert SG, Mooradian AD. Glucagon-like peptide-1 (GLP-1) response to acarbose in elderly type 2 diabetic subjects. *Diabetes Research and Clinical Practice* 56:101-106, 2002.

Scientific Publications (cont'd):

265. Brown WV et al for Rosuvastatin Study Group. Efficacy and safety of rosuvastatin compared with pravastatin and simvastatin in patients with hypercholesterolemia: a randomized, double-blind, 52-week trial. *Am Heart J.* 144:1036-1043, 2002
266. Franz, MJ, Bantle JP, Beebe CA, Brunzell JD, Jean-Louis Chiasson J-L, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M. Technical Review: Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related Complications. *Diabetes Care* 25:148- 198, 2002.
267. Haas MJ, Li J-P, Pun K, Mooradian AD. Partial characterization of a cerebral thyroid hormone responsive protein (THRP). *Archives of Biochemistry and Biophysics* 399:6-11, 2002.
268. Hasanain B, Mooradian AD. Antioxidants and their influence in diabetes. *Current Diabetes Reports* 2:448-456, 2002.
269. Mooradian AD, Kumar H. Thyroid disease in the elderly. In. *Primer on Geriatric Care.* D.E. Rosenblatt and V.S. Natarajan (eds). Printers Castle, Cochin 2002; pp 185-189.
270. Thurman JE, Mooradian AD. Alternative Therapy: Vitamin Use in the Elderly. In *Alternative Medicine for the Elderly.* P. Cherniak, N. Cherniack(eds), Springer Verlag, Berlin Heidelberg, 2003, pp91-109.
271. Chehade JM, Haas MJ, Mooradian AD. Diabetes-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1) expression. *Neurochem. Res.* 27:249-252, 2002.
272. Horani MH, Mooradian AD. Management of obesity in the elderly. Special considerations. *Treatments in Endocrinology* 1:387-398, 2002.
273. McMahon FG and the Sibutramine in Hypertensives Clinical Study Group. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. *J. Hum Hypertens.* 16: 5-11, 2002.
274. Mooradian AD, Haas MJ, Wong NCW, Chehade JH. Apolipoprotein A-I expression in rats is not altered by troglitazone. *Exp. Biol. Medicine* 227:1001-1005, 2002.
275. Blonde L, Rosenstock J, Mooradian AD, Piper BA, Henry D. Glyburide/metformin combination product is safe and efficacious in patients with type 2 diabetes failing sulphonylurea therapy. *Diabetes Obes Metab.* 4:368-375, 2002.

Scientific Publications (cont'd):

276. Mooradian AD, Haas MJ, Chehade JM. Age-related changes in rat cerebral occludin and zonula occludens-1 (ZO-1). *Mech.Ageing Devel.* 124: 143 – 146, 2003
277. Mooradian AD. Cardiovascular disease in Type 2 diabetes mellitus: Current management guidelines. *Arch. Intern. Med.* 163:33-40, 2003.
278. Haas MJ, Sawaf R, Horani MH, Gobal F, Wong NCW, Mooradian AD. Effect of chromium on apolipoprotein A-I expression in HepG2 cells. *Nutrition* 19:353-357, 2003.
279. Lam JK, Matsubara S, Mihara K, Zheng X, Mooradian AD, Wong NCW. Insulin induction of apolipoprotein A: role of SP1. *Biochemistry* 42:2680-2690, 2003.
280. Marston WA, Hanft J, Norwood P, Pollak R for the Dermagraft Diabetic Foot Ulcer Study Group. The efficacy and safety of Dermagraft in improving the healing of chronic diabetic foot ulcers. *Diabetes Care* 26: 1701-1705, 2003.
281. Haas MJ, Parseghian SA, Sajid RM, Mooradian, AD. Effect of thyroid hormone responsive protein (THRP) expression on PC12 cell survival. *Exp. Brain Res.* 150: 75-84, 2003.
282. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M. Evidence-based nutrition principles and recommendations for the treatment and prevention of diabetes and related complications. *Diabetes Care* 26 Suppl 1:S51-61, 2003.
283. Horani M, Mooradian AD. Diabetes and the blood-brain barrier. *Current Pharmaceutical Design* 9:833-840, 2003.
284. Oiknine R, Mooradian AD. Drug therapy of diabetes in the elderly. *Biomed Pharmacother.* 57:231-239, 2003.
285. Haas MJ, Horani M, Mreyoud A, Plummer B, Wong NCW, Mooradian AD. Suppression of apolipoprotein AI gene expression in Hep G2 cells by TNF α and IL-1 β . *Biochem. Biophys. Acta.* 1623: 120-128, 2003.
286. Hasnain BI, Mooradian AD. Clinical implications of recent trials of antioxidant therapy: What should we be telling our patients. *Cleveland Clin J Med.* 71: 327-334. 2004.
287. Ratner RE et al for the Amylin Study Group. Amylin replacement with pramlintide as an adjunct to insulin therapy improves long-term glycaemic and weight control in Type 1 diabetes mellitus: a 1-year, randomized controlled trial. *Diabetic Medicine* 21: 1204-1212, 2004.

Scientific Publications (cont'd):

288. Horani M, Gobal F, Haas MJ, Wong NCW, Mooradian AD. Cyclooxygenase (COX) inhibition is associated with down regulation of apolipoprotein AI (apo-AI) promoter activity in cultured hepatoma cell line-HepG2. *Metabolism* 53:174-181, 2004.
289. Mooradian AD, Haas MJ, Wong NCW. Transcriptional control of apolipoprotein A-I gene expression in diabetes mellitus. *Diabetes* 53:513-520, 2004.
290. Haas MJ, Wong NCW, Mooradian AD. Effect of glucosamine on apolipoprotein AI mRNA stabilization and expression in HepG2 cells. *Metabolism* 53: 766-771, 2004.
291. Albert SG, Mooradian AD. Low-dose recombinant human growth hormone (rhGH) as adjuvant therapy to life style modifications in the management of obesity. *J. Clin. Endocrinol Metab.* 89: 695-701, 2004.
292. Franz MJ, Bantle JP, Beebe CA, Brunzell JD, Chiasson JL, Garg A, Holzmeister LA, Hoogwerf B, Mayer-Davis E, Mooradian AD, Purnell JQ, Wheeler M; American Diabetes Association. Nutrition principles and recommendations in diabetes. *Diabetes Care.* 2004 Jan;27 Suppl 1:S36-46.
293. Horani, MH, Haas MJ, Mooradian AD. Rapid adaptive down regulation of oxidative burst induced by high dextrose in human umbilical vein endothelial cells. *Diabetes Research and Clinical Practice* 66:7-12, 2004.
294. Haas MJ, Mreyoud A, Fishman M, Mooradian AD. Microarray analysis of thyroid hormone induced changes in mRNA expression in the adult rat brain. *Neuroscience Lett.* 365:14-18, 2004.
295. Bhatt D et al on behalf of the CHARISMA Investigators. A global view of atherothrombosis: Baseline characteristics in the Clopidogrel for High Atherothrombotic Risk and Ischemic Stabilization, Management, and Avoidance (CHARISMA) trial. *Am. Heart J* 150: 401- 407, 2005.
296. Bolton WK et al for the ACTION I investigator group. Randomized trial of an inhibitor of formation of advanced glycation end products in diabetic nephropathy. *Am. J. Nephrol.* 24: 32- 40, 2004.
297. Bakris GL et al GEMINI Investigators. Metabolic effects of carvedilol vs metoprolol in patients with type 2 diabetes mellitus and hypertension: a randomized controlled trial. *JAMA.*292:2227- 2236, 2004.
298. Myers SE, Albert SG, Hass MJ, Clifton D, Mooradian AD. Pubertal changes in serum leptin levels in adolescents with type 1 diabetes: A controlled longitudinal study. *J. Pediatr. Endocrinol. Metab.*17:1653-1662, 2004.

Scientific Publications (cont'd):

299. Haas MJ, Horani MH, Wong NCW, Mooradian AD. Induction of apolipoprotein AI promoter by Sp1 is repressed by saturated fatty acids. *Metabolism: Clinical and Experimental*. 53:1342- 1348, 2004.
300. Hovsepyan MR, Haas MJ, Boyajyan AS, Guevorkyan AA, Mamikonyan AA, Myers SE, Mooradian AD. Astrocytic and neuronal biochemical markers in the sera of subjects with diabetes mellitus. *Neurosci. Lett*. 369:224-227., 2004.
301. Hoffman AR et al. on behalf of the T002 Study Group. Efficacy and Tolerability of an individualized Dosing Regimen for Adult Growth Hormone Replacement Therapy in Comparison with Fixed Body Weight-Based Dosing. *J Clin Endocrinol & Metab* 89: 3224-3233, 2004.
302. Mooradian AD. Towards single-tablet therapy for type 2 diabetes mellitus: rationale and recent developments. *Treat Endocrinol*. 3:279-287, 2004.
303. Mooradian AD. "Should the NCEP III guidelines be changed in elderly and younger persons at high Risk for cardiovascular events?" Commentary. *J. Gerontology* 60(5):598; 2005.
304. Oiknine R, Bernbaum M, Mooradian AD. A critical appraisal of the role of insulin analogues in the management of diabetes. *Drugs* 65(3):325-40., 2005.
305. Haas MJ, Fishman M, Mreyoud A, Mooradian AD. Thyroid hormone responsive protein (THRP) mediates thyroid hormone-induced cytotoxicity in primary neuronal cultures. *Exp. Brain Res*. 160: 424-432, 2005.
306. Albert SG, Hasnain, B, Ritter DG, Mooradian AD. Aspirin sensitivity of platelet aggregation in diabetes mellitus. *Diabetes Research and Clinical Practice* 70(2):195-9. 2005.
307. Chaudhry O, Mayo M, Mooradian AD. Undetectable serum creatinine in a paralyzed patient infected with human immunodeficiency virus (HIV). *Laboratory Medicine* 36:479-481, 2005.
308. Mooradian AD, Haas MJ, Batejko O, Hovsepyan M, Feman SS. Statins ameliorate endothelial barrier permeability changes in the cerebral tissue of streptozotocin induced diabetic rats. *Diabetes* 54(10):2977-82, 2005.
309. Marston WA for the Dermagraft Diabetic Foot Ulcer Study Group. Risk factors associated with healing chronic diabetic foot ulcers: The importance of hyperglycemia. *Ostomy Wound Manage*. 52: 26-39, 2006.
310. Wehmeier K, Beers A, Haas MJ, Wong NCW, Steinmeyer, A, Zugel U, Mooradian AD. Inhibition of apolipoprotein AI gene expression by 1, 25-dihydroxyvitamin D3. *Biochim. Biophys. Acta - Molecular and Cell Biology of Lipids*. 1737(1):16-26.2005.

Scientific Publications (cont'd):

311. Horani MH, Haas MJ, Mooradian AD. Suppression of hyperglycemia-induced superoxide formation and endothelin-1 gene expression by carvedilol. *Am. J. Therapeutics*. 213:2-7, 2006.
312. Oiknine RF, Mooradian AD. Thyroid disorders. In: *Principles and Practice of Geriatric Medicine*, 4th edition, MS John Pathy, AJ Sinclair, JE Morley, John Wiley and Sons, Ltd. 4th edition; Vol 2; 2006; pp: 1405-1414.
313. Mooradian AD, Haas MJ, Wadud K. Ascorbic acid and α -tocopherol down regulate apolipoprotein AI gene expression in HepG2 and Cac0-2 cell lines. *Metabolism: Clinical and Experimental* 55:159-167, 2006.
314. Mooradian AD. Diabetes and the consequences for the blood-brain barrier. In *Blood-Brain Barriers: From ontogeny to artificial interfaces*. R Dermietzel, D. C. Spray, M. Nedergaard (eds). Wiley-VCH, Weinheim, 2006, pp 649-670.
315. Mooradian AD. Diabetes as a model of premature aging. In: *Handbook of Models for Human Aging*. Michael Cohn Editor, 2006; pp687-695.
316. Horani MH, Haas MJ, Mooradian AD. Saturated, unsaturated, and trans fatty acids modulate oxidative burst induced by high dextrose in human umbilical vein endothelial cells. *Nutrition* 22:123-127, 2006.
317. Mooradian AD, Haas MJ, Wong NCW. The effect of select nutrients on serum high density lipoprotein cholesterol and apolipoprotein A-I levels. *Endocrine Reviews* 27:2-16, 2006.
318. Mooradian AD. Antioxidants and Diabetes. *Nestle Nutr Workshop Ser Clin Perform Programme*. 11:107-125, 2006.
319. Steiner G et al. for the BARI 2D Trial Investigators. Statement of the problem. *Am. J. Cardiol* 97[suppl]:3G-8G, 2006. Mooradian AD site PI and member of the Steering committee.
320. Brooks MM et al. for the BARI2D Trial Investigators. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial. *Am. J. Cardiol* 97[suppl]:9G-19G, 2006. Mooradian AD site PI and member of the Steering committee.
321. Magee MF, Isley WL for the BARI2D Trial Investigators. Rationale, design and methods for glycemic control in the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial. *Am. J. Cardiol* 97[suppl]:20G-30G, 2006. Mooradian AD site PI and member of the Steering committee.

Scientific Publications (cont'd):

322. Barsness GW, Gersh BJ, Brooks MM, Frye RL for the BARI2D Trial Investigators. Rationale for the revascularization arm of the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial. *Am. J. Cardiol* 97[suppl]:31G-40G, 2006. Mooradian AD site PI and member of the Steering committee.
323. Albu J, Gottlieb SH, August P, Nesto R, Orchard TJ for the BARI2D Trial Investigators. Modifications of coronary risk factors. *Am. J. Cardiol* 97[suppl]:41G-52G, 2006. Mooradian AD site PI and member of the Steering committee.
324. Sobel BE for the BARI2D Trial Investigators. Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 diabetes (BARI 2D) Trial: Synergies and opportunities. *Am. J. Cardiol* 97[suppl]:53G-58G, 2006. Mooradian AD site PI and member of the Steering committee.
325. Hlatky MA, Meslop KA, Boothroyd DB for the BARI2D Trial Investigators. Economic evaluation of alternative strategies to treat patients with diabetes mellitus and coronary artery disease. *Am. J. Cardiol* 97[suppl]:59G-65G, 2006. Mooradian AD site PI and member of the Steering committee.
326. Mooradian AD. Korenman, SG Endocrinology, in *Atlas of Internal Medicine*, Eugene Braunwald (ed). Third Edition, Springer, Philadelphia, 2007, pp. 121-179.
327. Case CC, Mooradian AD. Elevated plasma chromogranin A levels secondary to assay interference: A source of diagnostic confusion. *Endocrine Practice* 12:476-477, 2006.
328. Haas MJ, Horani MH, Parseghian SA, Mooradian AD. Statins prevent dextrose-induced endothelial barrier dysfunction possibly through inhibition of superoxide formation. *Diabetes* 55:474-479, 2006.
329. Morgentaler A for the National Tadalafil Study Group. Efficacy and safety of tadalafil across ethnic groups and various risk factors in men with erectile dysfunction: use of a novel non-inferiority study design. *J. Sexual Med.* 3: 492-503, 2006.
330. Beers A, Haas MJ, Wong NCW, Mooradian AD. Inhibition of apolipoprotein AI gene expression by tumor necrosis factor α : Roles for MEK/ERK and JNK Signaling. *Biochemistry* 45: 2408-2413, 2006.
331. Mooradian AD, Korenman SG. Management of the cardinal features of andropause. *Am. J. Therapeutics* 13: 145-160, 2006.
332. Mooradian AD, Bernbaum M, Albert SG. Narrative review: A rational approach to starting insulin therapy. *Ann. Intern. Med.* 145:125-34, 2006.

Scientific Publications (cont'd):

333. Mooradian AD. The dietary regulation of high density lipoprotein cholesterol. Commentary May 2006, International Atherosclerosis Society, <http://www.athero.org>; accessed July 15, 2006.
334. Hachem SB, Mooradian AD. Familial dyslipidaemias: An overview of genetics, pathophysiology and management. *Drugs* 66: 1949-1969, 2006.
335. Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML. American Diabetes Association. Nutrition Recommendations and Interventions for Diabetes–2006 A position statement of the American Diabetes Association. *Diabetes Care* 29:2140-2157, 2006.
336. Albert SG, Haas MJ, Mooradian AD. The Effects of recombinant human growth hormone (rhGH) supplementation on adipokines and C - reactive protein in obese subjects. *Growth Hormone & IGF Research* 17:19-25, 2007.
337. Chandurkar V, Mooradian A. Intermittent hyponatremia as a clinical presentation of adrenal insufficiency caused by pituitary adenoma. *Hospital Physician* 43: 51-55, 2007.
338. Albert SG, Obediah J, Parseghian SA, Hurley W, Mooradian AD. Severe insulin resistance associated with subcutaneous amyloid deposition. *Diabetes Research and Clinical Practice* 75:374-376, 2007.
339. Nowak FV, Mooradian AD. Endocrine Function and Dysfunction. *Encyclopedia of Gerontology: Age, Aging, and the Aged. (Second Edition)*J. E. Birren (ed); Elsevier Inc. San Diego, CA. Vol. 1; 2007; pp 480-493.
340. Bosi E et al Mooradian AD site PI. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Care* 30: 890-895, 2007.
341. Mooradian AD. The effect of nutrients on apolipoprotein AI gene expression. In *High Density Lipoproteins. From Basic Biology to Clinical Aspects*, Christopher. J. Fielding (ed), Wiley-VCH, Weinheim 2007; 399-423.
342. Garber AJ et al and Mooradian AD site PI. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thazolidenedione monotherapy: a randomized, placebo-controlled study. *Diabetes, Obesity and Metabolism* 9:166- 174, 2007.

Scientific Publications (cont'd):

343. Goldstein I et al for MOMENTUS Study Investigators. Efficacy and Safety of Tadalafil in Men with Erectile Dysfunction with a High Prevalence of Comorbid Conditions: Results from MOMENTUS: Multiple Observations in Men with Erectile Dysfunction in National Tadalafil Study in the US J. Sexual Med. 4: 166-175, 2007.
344. Mooradian AD, Haas MJ. Statins ameliorate glomerular permeability changes in streptozotocin-induced diabetic rats. Am. J. Therap. 14:41-45, 2007.
345. Mooradian AD, Albert SG, Hass MJ. Low serum HDL cholesterol in obese subjects with normal serum triglycerides: The role of insulin resistance and inflammatory cytokines. Diabetes, Obesity and Metabolism, 9:441-443, 2007.
346. Snyder PJ, Biller BM, Zagar A, Jackson I, Arafah BM, Nippoldt TB, Cook DM, Mooradian AD, Kwan A, Scism-Bacon J, Chipman JJ, Hartman ML. Effect of growth hormone replacement on bone mineral density in adult-onset growth hormone deficiency. J Bone Miner Res. 22:762-70. 2007.
347. Wylie-Rosett J, Albright AA, Apovian C, Clark NG, Delahanty L, Franz MJ, Hoogwerf B, Kulkarni K, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler M. 2006-2007 American Diabetes Association nutrition recommendations: issues for practice translation. J Am Diet Assoc. 107:1296-304, 2007.
348. Albert SG, Oiknine R, Parseghian S, Mooradian AD, Haas MJ, McPherson T. The effect of glucosamine on serum high density lipoprotein cholesterol and apolipoprotein AI levels in people with diabetes mellitus. Diabetes Care 30:2800-2803, 2007.
349. Mooradian AD, Haas MJ, Wehmeier K, Wong NCW. Obesity-related changes in high density lipoprotein metabolism. Obesity 16:1152-1160, 2008.
350. Lowman E, Mooradian AD. Macromelia masquerading as an acromegaloid syndrome in an adult with Klippel-Trenaunay syndrome. Endocrine Practice. 14:109-111, 2008.
351. Chehade J, Mooradian AD. Drug Therapy: Current and emerging agents in hyperglycemia. In: Diabetes in Old Age. 3rd edition, A.J. Sinclair and P. Finucane, (eds.), John Wiley & Sons Ltd., 2008 (in press).
352. Mooradian AD. Asymptomatic hyperthyroidism in older adults? Is it a distinct clinical and laboratory entity? Drugs & Aging 25(5):371-80, 2008.

Scientific Publications (cont'd):

353. Wehmeier, KR, Mazza, A, Hachem, S, Ken Ligaray K, Mooradian AD, Wong, NC, Haas MJ. Differential regulation of apolipoprotein A-I gene Expression by vitamin D receptor modulators *Biochim. Biophys. Acta* 1780:264-273, 2008.
354. American Diabetes Association, Bantle JP, Wylie-Rosett J, Albright AL, Apovian CM, Clark NG, Franz MJ, Hoogwerf BJ, Lichtenstein AH, Mayer-Davis E, Mooradian AD, Wheeler ML. Nutrition recommendations and interventions for diabetes: a position statement of the American Diabetes Association. *Diabetes Care*. Jan;31 Suppl 1:S61-78, 2008.
355. Palacio C, Masri G, Mooradian AD. A systematic review of the clinical trials of black cohosh in the management of menopausal symptoms. *Drugs and Aging* (in press) 2008.
356. Palacio CC, Alexandraki I, House J, Mooradian AD. A comparative study of unscheduled hospital readmissions in a resident staffed teaching service and a hospitalist based service. *Southern Medical Journal* (in press).
357. Reddy P, Mooradian AD. Diuretics: An update on the pharmacology and clinical uses. *American Journal of Therapeutics* (in press).
358. Mooradian A and the Bypass Angioplasty Revascularization Investigation 2 Diabetes Study Group. Baseline characteristics of patients with diabetes and coronary artery disease enrolled in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. *Am. Heart J.* 156:528-536, 2008.
359. Chehade JM, Lim W, Silverberg, AB, Mooradian AD. The incidence of Hashimoto's disease in nodular goiter: The concordance in serologic and cytologic findings. *Int. J. of Clinic. Practice* 2008 (in press).
360. Alexandraki A, Palacio CC, House J, Catalano C, Mooradian AD. Resource-based relative value scale analysis between teaching and non-teaching hospitalist services. *The Health Care Manager* (In press).